System and method for assessing lesions in tissue

ABSTRACT

A method and system for assessing lesion formation in tissue is provided. The system includes an electronic control unit (ECU). The ECU is configured to acquire values for first and second components of a complex impedance between the electrode and the tissue, and to calculate an index responsive to the first and second values. The ECU is further configured to process the ECI to assess lesion formation in the tissue.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.13/850,060, filed 25 Mar. 2013 (the '060 application), now U.S. Pat. No.______, which is a continuation of U.S. application Ser. No. 12/622,488,filed Nov. 20, 2009 (the '488 application), now U.S. Pat. No. 8,403,925,which in turn claims the benefit of and priority to U.S. application No.61/177,876, filed 13 May 2009 (the '876 application), now expired, andwhich is a continuation-in-part of U.S. application Ser. No. 12/253,637,filed 17 Oct. 2008 (the '637 application), now U.S. Pat. No. 8,449,535,which is a continuation-in-part of U.S. application Ser. No. 12/095,688,filed 30 May 2008 (the '688 application), now U.S. Pat. No. 9,271,782,which is a national stage application of International application no.PCT/US2006/061714, filed 6 Dec. 2006 (the '714 application), nowexpired, which in turn claims the benefit of U.S. application No.60/784,234, filed 6 Dec. 2005 (the '234 application), now expired. The'060 application, '488 application, '876 application, '637 application'688 application, '714 application and '234 are each hereby incorporatedby reference as though fully set forth herein.

BACKGROUND

a. Technical Field

This invention relates to a system and method for assessing theformation of lesions in tissue in a body. In particular, the instantinvention relates to a system and method for assessing the formation oflesions created by one or more electrodes on a therapeutic medicaldevice, such as an ablation catheter, in tissue, such as cardiac tissue.

b. Background Art

It is generally known that ablation therapy may be used to treat variousconditions afflicting the human anatomy. One such condition thatablation therapy finds a particular application is in the treatment ofatrial arrhythmias, for example. When tissue is ablated, or at leastsubjected to ablative energy generated by an ablation generator anddelivered by ablation catheter, lesions form in the tissue. Moreparticularly, electrodes mounted on or in ablation catheters are used tocreate tissue necrosis in cardiac tissue to correct conditions such asatrial arrhythmia (including, but not limited to, ectopic atrialtachycardia, atrial fibrillation, and atrial flutter). Arrhythmia cancreate a variety of dangerous conditions including irregular heartrates, loss of synchronous atrioventricular contractions and stasis ofblood flow which can lead to a variety of ailments and even death. It isbelieved that the primary cause of atrial arrhythmia is stray electricalsignals within the left or right atrium of the heart. The ablationcatheter imparts ablative energy (e.g., radiofrequency energy,cryoablation, lasers, chemicals, high-intensity focused ultrasound,etc.) to cardiac tissue to create a lesion in the cardiac tissue. Thislesion disrupts undesirable electrical pathways and thereby limits orprevents stray electrical signals that lead to arrhythmias.

One challenge with ablation procedures is in the assessment of thelesion formation as a result of the application of ablative energy tothe tissue. For example, it may be difficult to determine whether aparticular area of tissue has been ablated or not, the extent to whichablated tissue has been ablated, whether a lesion line is continuous orhas gaps therein, etc. Lesion formation has typically been fairlycrudely assessed using any one of a number of different empiricaltechniques.

One such technique depends on a subjective sense for catheter contactcombined with RF power settings, for example, and the duration theelectrode spends in contact with the tissue. Another technique employstemperature sensing. Ablation generators and their ablation cathetersmonitor temperature, but with the advent of saline cooled catheters,temperature has gone from an index of catheter temperature (and lessdirectly an index of tissue temperature), to a nearly useless indexprimarily reflecting irrigant saline flow. A further method relies onablation catheter electrogram signals. RF ablated myocardiumdemonstrates poor depolarization wavefront conduction and thus localelectrogram amplitude reduction and morphology changes are sometimes,but not consistently, observed. Accordingly, the assessment of lesionformation has ordinarily no direct objective basis.

The inventors herein have recognized a need for a system and method forassessing or the formation of lesions in tissue that will minimizeand/or eliminate one or more of the above-identified deficiencies.

SUMMARY

The present invention is directed to a system and method for assessingthe formation of lesions in a tissue in a body. The system according tothe present teachings includes an electronic control unit (ECU). The ECUis configured to acquire values for first and second components of acomplex impedance between the electrode and the tissue. The ECU isfurther configured to calculate an index responsive to the first andsecond values. The ECU is still further configured to process thecalculated index to assess lesion formation in a particular area of thetissue.

In an exemplary embodiment, the ECU is further configured to acquirevalues for a predetermined variable and to calculate the indexresponsive to the first and second complex impedance components and thevalue of the predetermined variable. In an exemplary embodiment thepredetermined variable comprises at least one of a contact force appliedby the electrode against the tissue, a contact pressure applied by theelectrode against the tissue, a temperature of the tissue, a change intemperature of the tissue, trabeculation of the tissue, saline flowrate, and blood flow rate.

In accordance with another aspect of the invention, an article ofmanufacture is provided. The article of manufacture includes acomputer-readable storage medium having a computer program encodedthereon for assessing the formation of lesions in tissue. The computerprogram includes code that, when executed by a computer, causes thecomputer to perform the steps of calculating an index responsive tovalues for first and second components of a complex impedance betweenthe electrode and the tissue, and processing the calculated index toassess lesion formation in a particular area of tissue.

In accordance with yet another aspect of the invention, a method forassessing the formation of lesions in a tissue in a body is provided.The method includes a first step of acquiring values for first andsecond components of a complex impedance between the electrode and thetissue. In a second step, an index responsive to the first and secondvalues is calculated. A third step includes processing the calculatedindex to assess lesion formation in a particular area of tissue.

Finally, in accordance with yet still another aspect of the invention,an automated catheter guidance system is provided. The system includes acatheter manipulator assembly and a catheter associated with thecatheter manipulator assembly. The catheter, in turn, has an electrodeassociated therewith. The system further includes a controllerconfigured to direct movement of the catheter in response to an indexcalculated from first and second components of a complex impedancebetween the electrode and a tissue in a body.

In one exemplary embodiment, the catheter manipulator assembly is arobotic catheter device cartridge, and the controller is configured todirect movement of the catheter device cartridge, and therefore, thecatheter. In another exemplary embodiment, the catheter manipulatorassembly comprises a magnetic field generator that is configured togenerate a magnetic field to control the movement of a magnetic elementlocated in or on the catheter, and therefore, to control the movement ofthe catheter.

The foregoing and other aspects, features, details, utilities, andadvantages of the present invention will be apparent from reading thefollowing description and claims, and from reviewing the accompanyingdrawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is diagrammatic view of a system in accordance with the presentteachings.

FIG. 2 is a simplified schematic diagram illustrating how impedance isdetermined in accordance with the present teachings.

FIG. 3 is a diagrammatic and block diagram illustrating the approach inFIG. 2 in greater detail.

FIG. 4 is a series of diagrams illustrating complex impedance variationsduring atrial tissue ablation and cardiac tissue contact over thirty(30) seconds.

FIG. 5 is a series of diagrams illustrating variations in a couplingindex during atrial tissue ablation and cardiac tissue contact over onehundred and sixty (160) seconds.

FIG. 6 is a screen display illustrating possible formats for presentinga coupling index to a clinician.

FIG. 7 is a flow diagram illustrative of an exemplary embodiment of amethod for assessing the proximity of an electrode to tissue inaccordance with present teachings.

FIGS. 8a and 8b are charts illustrating the relationship of electricalcoupling index (ECI) as a function of distance from tissue.

FIG. 9 is a flow diagram illustrative of another exemplary embodiment ofa method for assessing the proximity of an electrode to tissue inaccordance with present teachings.

FIG. 10 is a flow diagram illustrative of yet another exemplaryembodiment of a method for assessing the proximity of an electrode totissue in accordance with present teachings.

FIG. 11 is a chart illustrating the relationship of electrical couplingindex rate (or ECIR) as a function of distance from tissue.

FIG. 12 is a flow diagram illustrative of yet another exemplaryembodiment of a method for assessing the proximity of an electrode totissue in accordance with present teachings.

FIG. 13 is a chart illustrating an example employing a method ofproximity assessment involving a two-time scale approach.

FIGS. 14a-20b are flow diagrams illustrative of a various exemplaryembodiments of ECI-based methods for lesion assessment in tissue inaccordance with the present teachings.

FIGS. 21-27 are flow diagrams illustrative of various exemplaryembodiments of ALI-based methods for lesion assessment in tissue inaccordance with the present teachings.

FIG. 28 is a schematic diagram of a visualization, mapping, and 3Dnavigation system in accordance with the present teachings.

FIG. 29 is a diagrammatic view of a multi-electrode, array catheterillustrating one embodiment of a system in accordance with presentteachings.

FIG. 30 is an isometric diagrammatic view of a robotic catheter systemillustrating an exemplary layout of various system components inaccordance with the present teachings.

FIG. 31 is an isometric diagrammatic view of an exemplary embodiment ofa robotic catheter manipulator support structure in accordance with thepresent teachings.

FIG. 32 is a schematic diagram of a magnetic-based catheter manipulationsystem in accordance with the present teachings.

DETAILED DESCRIPTION

Referring now to the drawings wherein like reference numerals are usedto identify identical components in the various views, FIG. 1illustrates one embodiment of a system 10 for one or more diagnostic andtherapeutic functions including components providing an improvedassessment of, among other things, a degree of coupling between anelectrode 12 on a catheter 14 and a tissue 16 in a body 17. As will bedescribed in greater detail below, the degree of coupling can be usefulfor assessing, among other things, the degree of contact between theelectrode 12 and the tissue 16, the relative proximity of the electrode12 to the tissue 16, and the formation of lesions in the tissue 16. Inthe illustrated embodiment, the tissue 16 comprises heart or cardiactissue. It should be understood, however, that the present invention maybe used to evaluate coupling between electrodes and a variety of bodytissues. Further, although the electrode 12 is illustrated as part ofthe catheter 14, it should be understood that the present invention maybe used to assess a degree of coupling between any type of electrode andtissue including, for example, intracardiac electrodes, needleelectrodes, patch electrodes, wet brush electrodes (such as theelectrodes disclosed in commonly assigned U.S. patent application Ser.No. 11/190,724 filed Jul. 27, 2005, the entire disclosure of which isincorporated herein by reference) and virtual electrodes (e.g., thoseformed from a conductive fluid medium such as saline including thosedisclosed in commonly assigned U.S. Pat. No. 7,326,208 issued Feb. 5,2008, the entire disclosure of which is incorporated herein byreference). In addition to the catheter 14, the system 10 may includepatch electrodes 18, 20, 22, an ablation generator 24, a tissue sensingcircuit 26, an electrophysiology (EP) monitor 28, and a system 30 forvisualization, mapping and navigation of internal body structures whichmay include an electronic control unit 32 in accordance with the presentinvention and a display device 34, among other components.

The catheter 14 is provided for examination, diagnosis and treatment ofinternal body tissues such as the tissue 16. In accordance with oneembodiment of the invention, the catheter 14 comprises an ablationcatheter and, more particularly, an irrigated radio-frequency (RF)ablation catheter. It should be understood, however, that the presentinvention can be implemented and practiced regardless of the type ofablation energy provided (e.g., cryoablation, ultrasound, etc.) In anexemplary embodiment, the catheter 14 is connected to a fluid source 36having a biocompatible fluid such as saline through a pump 38 (which maycomprise, for example, a fixed rate roller pump or variable volumesyringe pump with a gravity feed supply from the fluid source 36 asshown) for irrigation. It should be noted, however, that the presentinvention is not meant to be limited to irrigated catheters. In anexemplary embodiment, the catheter 14 is also electrically connected tothe ablation generator 24 for delivery of RF energy. The catheter 14 mayinclude a cable connector or interface 40, a handle 42, a shaft 44having a proximal end 46 and a distal 48 end (as used herein, “proximal”refers to a direction toward the end of the catheter near the clinician,and “distal” refers to a direction away from the clinician and(generally) inside the body of a patient) and one or more electrodes 12,50, 52. The catheter 14 may also include other conventional componentsnot illustrated herein such as a temperature sensor, additionalelectrodes, and corresponding conductors or leads.

The connector 40 provides mechanical, fluid and electrical connection(s)for cables 54, 56 extending from the pump 38 and the ablation generator24. The connector 40 is conventional in the art and is disposed at aproximal end of the catheter 14.

The handle 42 provides a location for the clinician to hold the catheter14 and may further provide means for steering or the guiding shaft 44within the body 17. For example, the handle 42 may include means tochange the length of a guidewire extending through the catheter 14 tothe distal end 48 of the shaft 44 to steer the shaft 44. The handle 42is also conventional in the art and it will be understood that theconstruction of the handle 42 may vary. In an alternate exemplaryembodiment, the catheter 14 may be robotically driven or controlled.Accordingly, rather than a clinician manipulating a handle to steer orguide the catheter 14, and the shaft 44 thereof, in particular, a robotis used to manipulate the catheter 14.

The shaft 44 is an elongated, tubular, flexible member configured formovement within the body 17. The shaft 44 support the electrodes 12, 50,52, associated conductors, and possibly additional electronics used forsignal processing or conditioning. The shaft 44 may also permittransport, delivery and/or removal of fluids (including irrigationfluids and bodily fluids), medicines, and/or surgical tools orinstruments. The shaft 44 may be made from conventional materials suchas polyurethane and defines one or more lumens configured to houseand/or transport electrical conductors, fluids or surgical tools. Theshaft 44 may be introduced into a blood vessel or other structure withinthe body 17 through a conventional introducer. The shaft 44 may then besteered or guided through the body 17 to a desired location such as thetissue 16 with guidewires or other means known in the art.

The electrodes 12, 50, 52 are provided for a variety of diagnostic andtherapeutic purposes including, for example, electrophysiologicalstudies, catheter identification and location, pacing, cardiac mappingand ablation. In the illustrated embodiment, the catheter 14 includes anablation tip electrode 12 at the distal end 48 of the shaft 44, and apair of ring electrodes 50, 52. It should be understood, however, thatthe number, shape, orientation and purpose of the electrodes 12, 50, 52may vary.

The patch electrodes 18, 20, 22 provide RF or navigational signalinjection paths and/or are used to sense electrical potentials. Theelectrodes 18, 20, 22 may also have additional purposes such as thegeneration of an electromechanical map. The electrodes 18, 20, 22 aremade from flexible, electrically conductive material and are configuredfor affixation to the body 17 such that the electrodes 18, 20, 22 are inelectrical contact with the patient's skin. The electrode 18 mayfunction as an RF indifferent/dispersive return for the RF ablationsignal. The electrodes 20, 22 may function as returns for the RFablation signal source and/or an excitation signal generated by thetissue sensing circuit 26 as described in greater detail below. Inaccordance with one aspect of the present invention discussed below, theelectrodes 20, 22 are preferably spaced relatively far apart. In theillustrated embodiment, the electrodes 20, 22, are located on the medialaspect of the left leg and the dorsal aspect of the neck. The electrodes20, 22, may alternatively be located on the front and back of the torsoor in other conventional orientations.

The ablation generate 24 generates, delivers, and controls RF energyoutput by the ablation catheter 14. The generate 24 is conventional inthe art and may comprise the commercially available unit sold under themodel number IBI-1500T RF Cardiac Ablation Generator, available fromIrvine Biomedical, Inc. The generate 24 includes an RF ablation signalsource 54 configured to generate an ablation signal that is outputacross a pair of source connectors: a positive polarity connector SOURCE(+) which may connect to the tip electrode 12; and a negative polarityconnector SOURCE (−) which may be electrically connected by conductorsor lead wires to one of the patch electrodes 18, 20, 22 (see FIG. 2). Itshould be understood that the term connectors as used herein does notimply a particular type of physical interface mechanism, but is ratherbroadly contemplated to represent one or more electrical nodes. Thesource 54 is configured to generate a signal at a predeterminedfrequency in accordance with one or more user specified parameters(e.g., power, time, etc.) and under the control of various feedbacksensing and control circuitry as is know in the art. The source 54 maygenerate a signal, for example, with a frequency of about 450 kHz orgreater. The generator 24 may also monitor various parameters associatedwith the ablation procedure including impedance, the temperature at thetip of the catheter, ablation energy and the position of the catheterand provide feedback to the clinician regarding these parameters. Theimpedance measurement output by the generate 24, however, reflects themagnitude of impedance not only at the tissue 16, but the entireimpedance between the tip electrode 12 and the corresponding patchelectrode 18 on the body surface. The impedance output by the generate24 is also not easy to interpret and correlate to tissue contact by theclinician. In an exemplary embodiment, the ablation generate 24 maygenerate a higher frequency current for the purposes of RF ablation, anda second lower frequency current for the purpose of measuring impedance.

The tissue sensing circuit 26 provides a means, such as a tissue sensingsignal source 61, for generating an excitation signal used in impedancemeasurements and means, such as a complex impedance sensor 58, forresolving the detected impedance into its component parts. The signalsource 61 is configured to generate an excitation signal across sourceconnectors SOURCE (+) and SOURCE (−) (See FIG. 2). The source 61 mayoutput a signal having a frequency within a range from about 1 kHz toover 500 kHz, more preferably within a range of about 2 kHz to 200 kHz,and even more preferably about 20 kHz. In one embodiment, the excitationsignal is a constant current signal, preferably in the range of between20-200 μA, and more preferably about 100 μA. As discussed below, theconstant current AC excitation signal generated by the source 61 isconfigured to develop a corresponding AC response voltage signal that isdependent on the complex impedance of the tissue 16 and is sensed by thecomplex impedance sensor 58. The complex impedance is resolved into itscomponent parts (i.e., the resistance (R) and reactance (X) or theimpedance magnitude (|Z|) and phase angle (∠Z or φ)). Sensor 58 mayinclude conventional filters (e.g., bandpass filters) to blockfrequencies that are not of interest, but permit appropriatefrequencies, such as the excitation frequency, to pass, as well asconventional signal processing software used to obtain the componentparts of the measured complex impedance.

It should be understood that variations are contemplated by the presentinvention. For example, the excitation signal may be an AC voltagesignal where the response signal comprises an AC current signal.Nonetheless, a constant current excitation signal is preferred as beingmore practical. While in some situations there can be advantages tohaving an excitation signal frequency at or near the frequency of the RFablation signal, it should be appreciated that the excitation signalfrequency is preferably outside of the frequency range of the RFablation signal, which allows the complex impedance sensor 58 to morereadily distinguish the two signals, and facilitates filtering andsubsequent processing of the AC response voltage signal. Alternatively,the system can cycle each signal (RF ablation and excitation) on and offin alternating periods so they do not overlap in time. The excitationsignal frequency is also preferably outside the frequency range ofconventionally expected electrogram (EGM) signals in the frequency rangeof 0.05 Hz-1 kHz. Thus, in summary, the excitation signal preferably hasa frequency that is preferably above the typical EGM signal frequenciesand below the typical RF ablation signal frequencies.

The circuit 26 is also connected, for a purpose described below, acrossa pair of sense connectors: a positive polarity connector SENSE (+)which may connect to the tip electrode 12; and a negative polarityconnector SENSE (−) which may be electrically connected to one of thepatch electrodes 18, 20, 22 (see FIG. 2; note, however, that theconnector SENSE (−) should be connected to a different electrode of theelectrodes 18, 20, 22 relative to the connector SOURCE (−) as discussedbelow). It should again be understood that the term connectors as usedherein does not imply a particular type of physical interface mechanism,but is rather broadly contemplated to represent one or more electricalnodes.

Referring now to FIG. 2, connectors SOURCE (+), SOURCE (−), SENSE (+)and SENSE (−) form a three terminal arrangement permitting measurementof the complex impedance at the interface of the tip electrode 12 andthe tissue 16. Complex impedance can be expressed in rectangularcoordinates as set forth in equation (1):

Z=R+jX   (1)

where R is the resistance component (expressed in ohms); and X is areactance component (also expressed in ohms). Complex impedance can alsobe expressed polar coordinates as set forth in equation (2):

Z=r·e ^(jθ) =|Z|·e ^(j∠Z)   (2)

where |Z| is the magnitude of the complex impedance (expressed in ohms)and ∠Z=θ is the phase angle expressed in radians. Alternatively, thephase angle may be expressed in terms of degrees where

$\varphi = {\left( \frac{180}{\pi} \right){\theta.}}$

. Throughout the remainder of this specification, phase angle will bepreferably referenced in terms of degrees. The three terminals comprise:(1) a first terminal designated “A-Catheter Tip” which is the tipelectrode 12; (2) a second terminal designated “B-Patch 1” such as thesource return patch electrode 22; and (3) a third terminal designated“C-Patch 2” such as the sense return patch electrode 20. In addition tothe ablation (power) signal generated by the source 54 of the ablationgenerate 24, the excitation signal generated by the source 61 in thetissue sensing circuit 26 is also be applied across the sourceconnectors (SOURCE (+), SOURCE (−)) for the purpose of inducing aresponse signal with respect to the load that can be measured and whichdepends on the complex impedance. As described above, in one embodiment,a 20 kHz, 100 μA AC constant current signal is sourced along a path 60,as illustrated, from one connector (SOURCE (+), starting at node A)through the common node (node D) to a return patch electrode (SOURCE(−), node B). The complex impedance sensor 58 is coupled to the senseconnectors (SENSE (+), SENSE (−)), and is configured to determine theimpedance across a path 62. For the constant current excitation signalof a linear circuit, the impedance will be proportional to the observedvoltage developed across SENSE (+)/SENSE (−), in accordance with Ohm'sLaw: Z=V/I. Because voltage sensing is nearly ideal, the current flowsthrough the path 60 only, so the current through the path 62 (node D tonode C) due to the excitation signal is effectively zero. Accordingly,when measuring the voltage along the path 62, the only voltage observedwill be where the two paths intersect (i.e., from node A to node D).Depending on the degree of separation of the two patch electrodes (i.e.,those forming nodes B and C), an increasing focus will be placed on thetissue volume nearest the tip electrode 12. If the patch electrodes arephysically close to each other, the circuit pathways between thecatheter tip electrode 12 and the patch electrodes will overlapsignificantly and impedance measured at the common node (i.e., node D)will reflect impedances not only at the interface of the catheterelectrode 12 and the tissue 16, but also other impedances between thetissue 16 and the surface of body 17. As the patch electrodes are movedfurther apart, the amount of overlap in the circuit paths decreases andimpedance measured at the common node is only at or near the tipelectrode 12 of the catheter 14.

Referring now to FIG. 3, the concept illustrated in FIG. 2 is extended.FIG. 3 is a simplified schematic and block diagram of the three-terminalmeasurement arrangement of the invention. For clarity, it should bepointed out that the SOURCE (+) and SENSE (+) lines may be joined in thecatheter connector 40 or the handle 42 (as in solid line) or may remainseparate all the way to the tip electrode 12 (the SENSE (+) line beingshown in phantom line from the handle 42 to the tip electrode 12). FIG.3 shows, in particular, several sources of complex impedance variations,shown generally as blocks 64, that are considered “noise” because suchvariations do not reflect the physiologic changes in the tissue 16 orelectrical coupling whose complex impedance is being measured. Forreference, the tissue 16 whose complex impedance is being measured isthat near and around the tip electrode 12 and is enclosed generally by aphantom-line box 66 (and the tissue 16 is shown schematically, insimplified form, as a resistor/capacitor combination). One object of theinvention is to provide a measurement arrangement that is robust orimmune to variations that are not due to changes in or around the box66. For example, the variable complex impedance boxes 64 that are shownin series with the various cable connections (e.g., in the SOURCE (+)connection, in the SOURCE (−) and SENSE (−) connections, etc.) mayinvolve resistive/inductive variations due to cable length changes,cable coiling and the like. The variable complex impedance boxes 64 thatare near the patch electrodes 20, 22, may be more resistive/capacitivein nature, and may be due to body perspiration and the like over thecourse of a study. As will be seen, the various arrangements of theinvention are relatively immune to the variations in the blocks 64,exhibiting a high signal-to-noise (S/N) ratio as to the compleximpedance measurement for the block 66.

Although the SOURCE (−) and SENSE (−) returns are illustrated in FIG. 3as patch electrodes 20, 22, it should be understood that otherconfigurations are possible. In particular, the indifferent/dispersivereturn electrode 18 can be used as a return as well as another electrode50, 52 on the catheter 14, such as the ring electrode 50 as described incommonly assigned U.S. patent application Ser. No. 11/966,232 filed onDec. 28, 2007 and titled “System and Method for Measurement of anImpedance Using a Catheter such as an Ablation Catheter,” the entiredisclosure of which is incorporated herein by reference.

The EP monitor 28 is provided to display electrophysiology dataincluding, for example, an electrogram. The monitor 28 is conventionalin the art and may comprise an LCD or CRT monitor or anotherconventional monitor. The monitor 28 may receive inputs from theablation generate 24 as well as other conventional EP lab components notshown in the illustrated embodiment.

The system 30 is provided for visualization, mapping, and navigation ofinternal body structures. The system 30 may comprise the system havingthe model name EnSite NavX™ and commercially available from St. JudeMedical, Inc. and as generally shown with reference to commonly assignedU.S. Pat. No. 7,263,397 titled “Method and Apparatus for CatheterNavigation and Location and Mapping in the Heart,” the entire disclosureof which is incorporated herein by reference. Other systems may includethe Biosense Webster Carto™ System, commonly available fluoroscopysystems, or a magnetic location system such as the gMPS system fromMediguide Ltd. The system 30 may include the electronic control unit(ECU) 32 and the display device 34 among other components. However, inanother exemplary embodiment, the ECU 32 is a separate and distinctcomponent that is electrically connected to the system 30.

The ECU 32 is provided to acquire values for first and second componentsof a complex impedance between the catheter tip electrode 12 and thetissue 16 and to calculate an electrical coupling index (ECI) responsiveto the values with the coupling index indicative of a degree of couplingbetween the electrode 12 and the tissue 16. The ECU 32 preferablycomprises a programmable microprocessor or microcontroller, but mayalternatively comprise an application specific integrated circuit(ASIC). The ECU 32 may include a central processing unit (CPU) and aninput/output (I/O) interface through which the ECU 32 may receive aplurality of input signals including signals from the sensor 58 of thetissue sensing circuit 26 and generate a plurality of output signalsincluding those used to control the display device 34. In accordancewith one aspect of the present invention, the ECU 32 may be programmedwith a computer program (i.e., software) encoded on a computer storagemedium for determining a degree of coupling between the electrode 12 onthe catheter 14 and the tissue 16 in the body 17. The program includescode for calculating an ECI responsive to values for first and secondcomponents of the complex impedance between the catheter electrode 12and the tissue 16 with the ECI indicative of a degree of couplingbetween the catheter electrode 12 and the tissue 16.

The ECU 32 acquires one or more values for two component parts of thecomplex impedance from signals generated by the sensor 58 of the tissuesensing circuit 26 (i.e., the resistance (R) and reactance (X) or theimpedance magnitude (|Z|) and phase angle (φ) or any combination of theforegoing or derivatives or functional equivalents thereof). Inaccordance with one aspect of the present invention, the ECU 32 combinesvalues for the two components into a single ECI that provides animproved measure of the degree of coupling between the electrode 12 andthe tissue 16 and, in particular, the degree of electrical couplingbetween the electrode 12 and the tissue 16. As will be described ingreater detail below, the single ECI may provide an improved measure ofthe proximity of the electrode 12 relative to the tissue 16, as well asimproved assessment of lesion formation in the tissue 16.

Validation testing relating to the coupling index was performed in apre-clinical animal study. The calculated coupling index was compared topacing threshold as an approximation of the degree of coupling. Pacingthreshold was used for comparison because it is objective andparticularly sensitive to the degree of physical contact between the tipelectrode and tissue when the contact forces are low and the currentdensity paced into the myocardium varies. In a study of seven swine(n=7, 59+/−3 kg), a 4 mm tip irrigated RF ablation catheter wascontrolled by an experienced clinician who scored left and right atrialcontact at four levels (none, light, moderate and firm) based onclinician sense, electrogram signals, three-dimensional mapping, andfluoroscopic images. Several hundred pacing threshold data points wereobtained along with complex impedance data, electrogram amplitudes anddata relating to clinician sense regarding contact. A regressionanalysis was performed using software sold under the registeredtrademark “MINITAB” by Minitab, Inc. using the Log 10 of the pacingthreshold as the response and various impedance parameters as thepredictor. The following table summarizes the results of the analysis:

Regression R{circumflex over ( )}2 Model Regression Factors in ModelR{circumflex over ( )}2 R{circumflex over ( )}2_adj 1 R1_mean 43.60%43.50% (p < 0.001) 2 X1_mean 35.70% 35.50% (p < 0.001) 3 X1_mean R1_mean47.20% 46.90% (p < 0.001) (p < 0.001) 4 X1_stdev R1_stdev X1_meanR1_mean 48.70% 48.00% (p = 0.300) (p = 0.155) (p < 0.001) (p < 0.001) 5R1_P-P X1_stdev R1_stdev X1_mean R1_mean 49.00% 48.10% (p = 0.253) (p =0.280) (p = 0.503) (p < 0.001) (p < 0.001)

As shown in the table, it was determined that a mean value forresistance accounted for 43.5% of the variation in pacing thresholdwhile a mean value for reactance accounted for 35.5% of the variation inpacing threshold. Combining the mean resistance and mean reactancevalues increased the predictive power to 46.90% demonstrating that anECI based on both components of the complex impedance will yieldimproved assessment of coupling between the catheter electrode 12 andthe tissue 16. As used herein, the “mean value” for the resistance orreactance may refer to the average of N samples of a discrete timesignal x_(i) or a low-pass filtered value of a continuous x(t) ordiscrete x(t_(i)) time signal. As shown in the table, adding morecomplex impedance parameters such as standard deviation and peak to peakmagnitudes can increase the predictive power of the ECI. As used herein,the “standard deviation” for the resistance or reactance may refer tothe standard deviation, or equivalently root mean square (rms) about themean or average of N samples of a discrete time signal x_(i) or thesquare root of a low pass filtered value of a squared high pass filteredcontinuous x(t) or discrete x(t_(i)) time signal. The “peak to peakmagnitude” for the resistance or reactance may refer to the range of thevalues over the previous N samples of the discrete time signal x_(i) orthe k^(th) root of a continuous time signal [abs(x(t))]^(k) that hasbeen low pass filtered for sufficiently large k>2. It was furtherdetermined that, while clinician sense also accounted for significantvariation in pacing threshold (48.7%)—and thus provided a good measurefor assessing coupling—the combination of the ECI with clinician sensefurther improved assessment of coupling (accounting for 56.8% of pacingthreshold variation).

Because of the processing and resource requirements for more complexparameters such as standard deviation and peak to peak magnitude, andbecause of the limited statistical improvement these parametersprovided, it was determined that the most computationally efficient ECIwould be based on mean values of the resistance (R) and reactance (X),and more specifically, the equation: ECI=a*Rmean+b*Xmean+c.

From the regression equation, and using a 4 mm irrigated tip catheter,the best prediction of pacing threshold—and therefore coupling—wasdetermined to be the following equation (³):

ECI=Rmean−5.1*Xmean   (3)

where Rmean is the mean value of a plurality of resistance values andXmean is the mean value of a plurality of reactance values. It should beunderstood, however, that other values associated with the impedancecomponents, such as a standard deviation of a component or peak to peakmagnitude of a component which reflect variation of impedance withcardiac motion or ventilation, can also serve as useful factors in theECI. Further, although the above equation and following discussion focuson the rectangular coordinates of resistance (R) and reactance (X), itshould be understood that the ECI could also be based on valuesassociated with the polar coordinates impedance magnitude (|Z|) andphase angle (φ) or indeed any combination of the foregoing components ofthe complex impedance and derivatives or functional equivalents thereof.Finally, it should be understood that coefficients, offsets and valueswithin the equation for the ECI may vary depending on, among otherthings, the specific catheter used, the patient, the equipment, thedesired level of predictability, the species being treated, and diseasestates. In accordance with the present invention, however, the couplingindex will always be responsive to both components of the compleximpedance in order to arrive at an optimal assessment of couplingbetween the catheter electrode 12 and the tissue 16.

The above-described analysis was performed using a linear regressionmodel wherein the mean value, standard deviation, and/or peak to peakmagnitude of components of the complex impedance were regressed againstpacing threshold values to enable determination of an optimal ECI. Itshould be understood, however, that other models and factors could beused. For example, a nonlinear regression model may be used in additionto, or as an alternative to, the linear regression model. Further, otherindependent measures of tissue coupling such as atrial electrogramscould be used in addition to, or as an alternative to, pacingthresholds.

Validation testing was also performed in a human trial featuring twelvepatients undergoing catheter ablation for atrial fibrillation. Thepatients were treated using an irrigated, 7 French radio frequency (RF)ablation catheter with a 4 mm tip electrode operating at a standardsetting of a 50° C. tip temperature, 40W power, and 30 ml/min. flow rate(adjusted accordingly proximate the esophagus). An experienced clinicianplaced the catheter in the left atrium in positions of unambiguousnon-contact and unambiguous contact (with varying levels of contactincluding “light,” “moderate,” and “firm”) determined throughfluoroscopic imaging, tactile feedback electrograms, clinicianexperience, and other information. In addition to impedance,measurements of electrogram amplitudes and pacing thresholds wereobtained for comparison. Each measure yielded corresponding changes invalue as the catheter electrode moved from a no-contact position to acontact position. In particular, electrogram amplitudes increased from0.14+/−0.16 to 2.0+/−1.9 mV, pacing thresholds decreased from 13.9+/−3.1to 3.1+/−20 mA and the ECI increased from 118+/−15 to 145+/−24 (withresistance increasing from 94.7+/−11.0 to 109.3+/−15.1 Ω and reactancedecreasing from −4.6+/−0.9 to −6.9+/−2Ω). Further, the ECI increased(and resistance increased and reactance decreased) as the catheterelectrode was moved from a “no-contact” (115+/−12) position to “light,”(135+/−15) “moderate,” (144+/−17) and “firm” (159+/−34) positions. Thesemeasurements further validate the use of the ECI to assess couplingbetween the catheter electrode 12 and the tissue 16. The calculated ECIand clinician sense of coupling were again compared to pacing thresholdas an approximation of the degree of coupling. A regression analysis wasperformed using a logarithm of the pacing threshold as the response andvarious impedance parameters and clinician sense as predictors. Fromthis analysis, it was determined that clinician sense accounted forapproximately 47% of the variability in pacing threshold. The additionof the ECI, however, with clinician sense resulted in accounting forapproximately 51% of the variability in pacing threshold—furtherdemonstrating that the ECI can assist clinicians in assessing couplingbetween the catheter electrode 12 and the tissue 16.

Referring now to FIGS. 4-5, a series of timing diagrams (in registrationwith each other) illustrate a comparison of atrial electrograms relativeto changes in resistance and reactance (FIG. 4) and the composite ECI(FIG. 5). As noted hereinabove, atrial electrograms are one traditionalmeasurement for assessing coupling between the catheter electrode 12 andthe tissue 16. As shown in FIG. 4, the signal amplitude of the atrialelectrogram (labeled “ABL D-2” in FIG. 4) increases when the catheterelectrode 12 moves from a position of “no contact” to “contact” with thetissue 16. Similarly, measured resistance (R) increases and reactance(X) decreases and become more variable (FIG. 4) and the calculated ECIincreases (FIG. 5), further demonstrating the utility of the ECI inassessing coupling between the electrode 12 and the tissue 16.

The human validation testing also revealed that the ECI varied dependingon tissue types. For example, the ECI tended to be higher when thecatheter electrode was located inside a pulmonary vein than in the leftatrium. As a result, in accordance with another aspect of the presentinvention, the ECI may be used in identifying among tissue types (e.g.,to identify vascular tissue as opposed to trabeculated and myocardialtissue). Further, because force sensors may not adequately estimate theamount of energy delivered into tissue in constrained regions, such asthe pulmonary vein or trabeculae, the inventive ECI may provide a moremeaningful measure of ablation efficacy than force sensors. In addition,in certain situations, it may be advantageous to utilize both a forcesensor and the ECI. For example, if a particular location indicates alow reading on a force sensor but a high ECI reading, it can be anindication that the catheter is in a constrained region or is in closeproximity to trabeculated tissue. Combining the readings of the forcesensor, ECI and a mapping system allows the system to map tissue typeson the 3D map, as well as differentiate between trabeculated tissue orconstrained regions and smooth tissue with significant electrode appliedforce.

Impedance measurements are also influenced by the design of the catheter14, the connection cables 56, or other factors. Therefore, the ECI maypreferably comprise a flexible equation in which coefficients andoffsets are variable in response to design parameters associated withthe catheter 14 (e.g., ECI=a*Rmean+b*Xmean+c). The catheter 14 mayinclude a memory such as an EEPROM that stores numerical values for thecoefficients and offsets or stores a memory address for accessing thenumerical values in another memory location (either in the catheterEEPROM or in another memory). The ECU 32 may retrieve these values oraddresses directly or indirectly from the memory and modify the ECIaccordingly.

The physical structure of the patient is another factor that mayinfluence impedance measurements and the ECI. Therefore, the ECU 32 mayalso be configured to offset or normalize the ECI (e.g., by adjustingcoefficients or offsets within the index) responsive to an initialmeasurement of impedance or another parameter in a particular patient.In addition, it may be beneficial to obtain and average values for theECI responsive to excitation signals generated by the source 61 atmultiple different frequencies.

Referring now to FIG. 6, the display device 34 is provided to presentthe ECI in a format useful to the clinician. The device 34 may alsoprovide a variety of information relating to visualization, mapping, andnavigation, as is known in the art, including measures of electricalsignals, two and three dimensional images of the tissue 16, andthree-dimensional reconstructions of the tissue 16. The device 34 maycomprise an LCD monitor or other conventional display device. Inaccordance with another aspect of the present invention, the ECI may bedisplayed in one or more ways to provide easy interpretation andcorrelation to tissue contact and/or proximity of the electrode 12 tothe tissue 16 for the clinician. Referring to FIG. 6, the ECI may bedisplayed as a scrolling waveform 68. The ECI may also be displayed as ameter 70 which displays the one second average value of the ECI. Foreither the scrolling waveform 68 or the meter 70, upper and lowerthresholds 72, 74 may be set (either pre-programmed in the ECU 32 orinput by the user using a conventional I/O device). Characteristics ofthe waveform 68 and/or the meter 70 may change depending upon whetherthe value of the ECI is within the range set by the thresholds (e.g.,the waveform 68 or the meter 70 may change colors, such as from green tored, if the value of the ECI moves outside of the range defined by thethresholds). Changes to the ECI may also be reflected in changes to theimage of the catheter 14 and/or the catheter electrode 12 on the displaydevice 34. For example, the catheter electrode 12 may be displayed onthe screen (including within a two or three dimensional image orreconstruction of the tissue) as a beacon 76. Depending on the value ofthe ECI, the appearance of the beacon 76 may change. For example, thecolor of the beacon 76 may change (e.g., from green to red) and/or linesmay radiate outwardly from the beacon 76 as the index falls above, belowor within a range of values. In another exemplary embodiment, the lengthof the splines of the beacon 76 may continuously vary with the ECI.

In summary, the degree of coupling between a catheter electrode 12 andthe tissue 16, which may be used to assess the proximity of theelectrode 12 to the tissue 16, may be assessed through several methodsteps in accordance with one embodiment of the invention. First, anexcitation signal is applied between the electrode 12 and a referenceelectrode such as the patch electrode 22 between connectors SOURCE (+)and SOURCE (−) along the first path 60 (see FIG. 2). As discussed above,the signal source 61 of the tissue sensing circuit 26 may generate theexcitation signal at a predetermined frequency or frequencies. Thisaction induces a voltage along the path 62 between the electrode 12 andanother reference electrode such as the patch electrode 20. The voltagemay be measured by the sensor 58 which resolves the sensed voltage intocomponent parts of the complex impedance at the tissue 16. As a result,the ECU 32 acquires values for the components of the complex impedance.The ECU 32 then calculates a ECI responsive to the values that isindicative of a degree of coupling between the electrode 12 and thetissue 16. The index may then be presented to a clinician in a varietyof forms including by display on the display device 34 as, for example,the waveform 68, the meter 70, or the beacon 76.

An ECI formed in accordance with the teaching of the present inventionmay be useful in a variety of applications. As shown in the embodimentillustrated in FIG. 1, the ECI can be used as part of the system 10 forablation of the tissue 16. The ECI provides an indication of the degreeof electrical coupling between the tip electrode 12 and the tissue 16,thereby assisting in the safe and effective delivery of ablation energyto the tissue 16.

The ECI may further provide an indication of the proximity ororientation of the tip electrode 12 to the adjacent tissue 16. Referringto FIGS. 1 and 2, the signal source 61 of the sensing circuit 26 maygenerate excitation signals across source connectors SOURCE (+) andSOURCE (−) defined between the tip electrode 12 and the patch electrode22, and also between the ring electrode 50 and the patch electrode 22.The impedance sensor 58 may then measure the resulting voltages acrosssense connectors SENSE (+) and SENSE (−)) defined between the tipelectrode 12 and the patch electrode 20, and also between the ringelectrode 50 and the patch electrode 22. In an exemplary embodiment, themeasurements for the tip 12 and the ring 50 are taken at differentfrequencies or times. The ECU 32 may compare the measured valuesdirectly or, more preferably, determine an ECI for each of theelectrodes 12, 50 responsive to the measured values, and compare the twoECIs. Differences between the measured impedance or ECI for theelectrodes 12, 50 may indicate that the electrode 12 is disposed at anangle (as well as the degree of that angle) relative to the tissue 16.

It should be understood that the electrode 50 is used for exemplarypurposes only. Similar results could be obtained with other electrodesdisposed proximate the tip electrode 12 or from using a split tipelectrode. For example, in another exemplary embodiment, the ECI mayprovide an indication of proximity or orientation of the catheter's tipto adjacent tissue by employing two or more electrodes near the tip. Inone such embodiment, the tip electrode 12 is used together with andadjacent the ring electrode 50 to provide two independent measures ofcomplex impedance and ECI. This is accomplished in the manner describedwith respect to FIGS. 1-3, but relies on separate SOURCE and SENSEcircuits and connections that operate on different frequencies, or thatare time division multiplexed to achieve independence. Cutaneous patchelectrodes 20, 22 may be used in common for both tip and ring electrodeimpedance and ECU determinations. The ECU 32 may employ the twoimpedance measurements directly or operate on the difference of theimpedances or ECIs. When in non-contact and of a defined proximityregion, the tip and ring ECIs will both be constant and exhibit a fixeddifference (depending on electrode design). Changes in this differentialimpedance or ECI reflect proximity of one (or both) electrodes totissue. Once the tip electrode is in contact, the value of thedifferential ECI may indicate the angle of incidence of the catheter tipwith tissue. Similar results could be obtained from other electrodesdisposed near the tip electrode 12 or from using a split-tip electrode.

As briefly described above, the present invention may also be used as aproximity sensor to assess or determine the proximity of the electrode12 to the tissue 16, as well as to assess the formation of lesions inthe tissue 16. With respect to proximity assessment, as an electrode,such as the electrode 12, approaches the tissue 16, the impedancechanges as does the ECI. The ECI is therefore indicative of theproximity of the electrode 12 to the tissue 16. In some applications,the general position (with a frame of reference) and speed of the tip ofthe catheter 14 and the electrode 12 are known (although the proximityof the electrode 12 to the tissue 16 is unknown). As will be describedin greater detail below, this information can be combined to define avalue (the “electrical coupling index rate” or ECIR) that is indicativeof the rate of change in the ECI as the electrode 12 approaches thetissue 16 and which may provide an improved measure of the proximity ofthe electrode 12 to the tissue 16. This information can be used, forexample, in robotic catheter applications to slow the rate of approachprior to contact, and also in connection with a transseptal accesssheath having a distal electrode to provide an indication that thesheath is approaching (and/or slipping away from) the septum.

In exemplary embodiment, the raw calculated ECI may be used to assessthe proximity of the electrode 12 to the tissue 16. This particularembodiment provides a relatively simple discrimination of proximity. TheECU 32 calculates the ECI as described in detail above. The calculatedECI may then be used to assess the proximity of the electrode 12 to thetissue 16. FIG. 7 illustrates an exemplary embodiment of a method forassessing the proximity using the ECI.

In this particular embodiment, a current ECI is calculated in a firststep 78. In a second step 80, the calculated ECI is evaluated todetermine whether the electrode 12 is within a predetermined distancefrom the tissue 16, in contact with the tissue 16, or further away fromthe tissue 16 than the predetermined distance. More particularly, in afirst substep 82 of second step 80, an ECI range 84 is defined thatcorrelates to a predetermined distance from the tissue 16. In anexemplary embodiment provided for illustrative purposes only, thepredetermined distance is 2 mm, and so the ECI range 84 has a firstthreshold value 86 that corresponds to 0 mm from the tissue 16 (i.e.,the electrode is in contact with the tissue), and a second thresholdvalue 88 that corresponds to location that is 2 mm from the tissue 16.These thresholds may be set by either preprogramming them into the ECU32, or a user may input them using a conventional I/O device. In asecond substep 90 of second step 80, the calculated ECI is compared tothe predefined ECI range 84. Based on this comparison, the relativeproximity of the electrode 12 is determined.

More particularly, if the calculated ECI is within the range 84, thenthe electrode 12 is deemed to be in “close proximity” of the tissue 16.In this particular embodiment, if the electrode is within 0-2 mm of thetissue, it is deemed to be in “close proximity.” If the calculated ECIfalls below the first threshold value 86, then the electrode 12 isdeemed to be in contact with the tissue 16. Finally, if the calculatedECI falls outside of the second threshold value 88, then the electrode12 is deemed to not be in close proximity of the tissue 16, but ratheris further away than the predetermined distance, which, in thisembodiment would mean that the electrode 12 is further than 2 mm fromthe tissue 16. It should be noted that a range of 0-2 mm is usedthroughout as the range corresponding to “close proximity.” However,this range is provided for exemplary purposes only and is not meant tobe limiting in nature. Rather, any other ranges of distance from thetissue 16 may be used depending on the application.

FIGS. 8a and 8b are provided to illustrate how the above describedmethodology may be applied. FIG. 8a illustrates examples of the resultsof ECI calculations that are meant to correspond to calculationsrepresenting three different angles of approach—0, 60, and 90 degrees—ofthe electrode 12 to the tissue 16. FIG. 8b illustrates examples of theresults of ECI calculations that are meant to correspond to calculationsresulting from the use of different types of catheters (i.e., CATH A,CATH B, and CATH C), which may influence the ECI calculations. It shouldbe noted that the illustrated calculations do not correspond to actualtest data or calculations made during an actual procedure, but ratherare provided solely for illustrative purposes. In this example, thepredetermined distance from the heart that is deemed to be “closeproximity” was 0 to 2 mm.

As seen in FIG. 8a , in this particular example, the calculations foreach angle of approach are fairly consistent with each other. As such, asingle ECI range 84 may be defined that can be compared to anycalculated ECI regardless of the angle of approach. In this particularexample, the ECI range 84 is defined by the first threshold 86 having avalue of 135, which corresponds to 0 mm from the tissue 16, and thesecond threshold 88 having a value of 125, which corresponds to 2 mmfrom the tissue 16. When the electrode is more than approximately 2 mmaway from the tissue 16, the ECI is below 125, the second threshold 88of the ECI range 84, and is relatively stable. As the electrode 12approaches the tissue 16, however, the ECI begins to increase. When theelectrode 12 is approximately 2 mm away, the ECI is around 125, which,again, is the second threshold 88 of the ECI range 84. As the electrode12 continues to get closer the tissue 16, and therefore in closerproximity to the tissue 16, the ECI continues to increase. When theelectrode 12 reaches the tissue 16 and makes contact, the ECI is at thefirst threshold 86 of approximately 135.

With respect to FIG. 8b , in this particular example, the illustratedcalculations are spaced apart, as opposed to being closely groupedtogether. As such, a single ECI range 84 cannot be defined that wouldallow for the comparison with any calculated ECI. A number of factorsmay contribute to the spacing out of the calculations. For example, thetype of catheter used, the particular environment in which thecalculations are made, attributes of the patient, etc. may allcontribute to the resulting spacing out of the calculations. Tocompensate for such factors, an offset is used. More particularly, ifone or more contributory factors are present, the clinician is able toenter such information into the ECU 32 via a user interface for example,which will then be configured to add or subtract a defined offset fromone or both of the calculated ECI and/or the ECI range. In an exemplaryembodiment, ECU 32 may be programmed with one or more offsets, or theoffset(s) may be entered by a user using a conventional I/O interface.Accordingly, in one exemplary embodiment, rather than simply comparingthe ECI to an ECI range, an offset is added to or subtracted from eitherthe ECI range, or the calculated ECI itself. In either instance, theadded or subtracted offset performs a scaling function that allows forthe comparison described above to be made.

In the particular example illustrated in FIG. 8b , the ECI range 84 is abaseline ECI range defined by the first threshold 86 having a value of135, which corresponds to 0 mm from the tissue 16, and the secondthreshold 88 having a value of 125, which corresponds to 2 mm from thetissue 16. If the particular procedure is one in which an offset wouldapply, the ECU 32 makes the necessary adjustments, and then themethodology continues as described above with respect to FIG. 7. Whenthe electrode is more than approximately 2 mm away from the tissue 16,the ECI is below 125, the second threshold 88 of the ECI range 84, andis relatively stable. As the electrode 12 approaches the tissue 16,however, the ECI begins to increase. When the electrode 12 isapproximately 2 mm away, the ECI is around 125, which, again, is thesecond threshold 88 of the ECI range 84. As the electrode 12 continuesto get closer the tissue 16, and therefore in closer proximity to thetissue 16, the ECI continues to increase. When the electrode 12 reachesthe tissue 16 and makes contact, the ECI is at the first threshold 86 ofapproximately 135.

Accordingly, by knowing the ECI (whether as calculated and/or with anoffset) and comparing it to the ECI range representing a predetermineddistance from the tissue 16 (which may include an offset depending onthe circumstances), one can easily determine whether the electrode 12 isin contact with, in close proximity to, or far away from the hearttissue 16.

In another exemplary embodiment, rather than comparing a calculatedfinite ECI to a predefined range, the rate of change of the ECI

$\left( {{i.e.},\frac{{ECI}}{t}} \right)$

may be evaluated and used to assess the proximity of the electrode 12 tothe tissue 16. When the electrode 12 is within a predetermined distancefrom the tissue 16, the rate of change of the ECI or the change in theslope between ECIs over a predetermined amount of time

$\left( {{i.e.},\frac{^{2}{ECI}}{t^{2}}} \right)$

is most evident, and therefore, the rate of change in the ECI is greaterthan when either in contact with or far away from the tissue 16.Accordingly, it follows that when the rate of change of the ECI over apredetermined period of time is within a certain range or equals aparticular rate, one may be able to determine whether the electrode 12is within a predetermined distance or in close proximity to the tissue16.

FIG. 9 illustrates one exemplary embodiment of a methodology that usesthe rate of change of the ECI. In this embodiment, a storage medium 92(i.e., memory 92) is provided to store a predetermined number ofpreviously calculated ECIs. The memory 92 may be part of the ECU 32 (SeeFIG. 1), or may be a separate component (or part of another component)that is accessible by the ECU 32 such that the ECU 32 may retrieve thestored ECIs. In an exemplary embodiment, the ECU 32 is configured toaccess the memory 92 and to calculate the rate of change in the ECI orthe slope of a line drawn between a current or most recent ECIcalculation and one or more previously calculated ECIs. If the rate ofchange or slope meets a predetermined value or falls within apredetermined or predefined range, then the ECU 32 will recognize thatthe ECI has changed at a certain rate, and therefore, that electrode 12is within a certain distance of the tissue 16.

Accordingly, with specific reference to FIG. 9, in a first step 94 ofthis particular embodiment, a current ECI is calculated. In a secondstep 96, the ECU 32 accesses the memory 92 to retrieve one or morepreviously calculated ECIs. In a third step 98, the rate of change/slopebetween the current ECI and the one or more previously calculated ECIsis calculated. In a fourth step 100, the ECU 32 determines whether theelectrode 12 is in close proximity to the tissue 16 based on the rate ofchange in the ECI.

This embodiment is particularly useful because the raw ECI is not beingdirectly compared to a range of ECIs. Rather, because it is a rate ofchange or slope calculation, it does not matter what the magnitude ofthe ECI is, as it is the rate of change of the ECI that is beingevaluated. Accordingly, it provides a more normalized approach forassessing proximity.

In an exemplary embodiment, whether the system 10 uses the raw ECI orthe rate of change of the ECI to assess proximity, the system 10 isfurther configured to provide an indication to the clinicianmanipulating the catheter 14 or to a controller of a roboticallycontrolled device that drives the catheter 14 that the electrode 12 isin “close proximity” to the tissue 16. In one exemplary embodiment, theECU 32 is configured to generate a signal representative of an indicatorthat the electrode 12 is within the certain predetermined distance ofthe tissue 16 (e.g., 0-2 mm). In such an instance, this indicatorindicates that the electrode 12 is in close proximity of the tissue 16and allows the clinician or robotic controller to adjust its conductaccordingly (e.g., slow down the speed of approach). Such an indicatormay be visually displayed on the display 34 of the system in the samemanner described above with respect to the display of the ECI, may bedisplayed in a graphical form, may be in the form of an audible warning,or may comprise any other known indicators. With respect to roboticapplications, the signal may be transmitted by the ECU 32 to acontroller of the robotic device, which receives and processes thesignal and then adjusts the operation of the robot as necessary. Inother exemplary embodiments, the ECU 32 may also provide indicators thatthe electrode 12 is far away from the tissue 16 (i.e., further away thana predetermined distance), and/or that the electrode 12 is in contactwith the tissue 16.

In another exemplary embodiment, the ECI may be used, in part, tocalculate an electrical coupling index rate (ECIR). The resulting ECIRcan, in turn, be used to assess the proximity of the electrode 12 to thetissue 16. In an exemplary embodiment, the ECU 32 is configured tocalculate the ECIR, however, in other exemplary embodiments otherprocessors or components may be used to perform the calculation. As willbe described below, this particular embodiment provides a graded levelof proximity.

In simple terms, the ECIR is calculated by dividing the change in ECI bythe change in distance or position of the electrode 12 over apredetermined period of time. More specifically, the ECIR is calculatedusing the following equation (4):

$\begin{matrix}{{{ECIR}\mspace{14mu} \text{:=}\mspace{14mu} \frac{{ECI}}{s}} = \frac{{{ECI}}\text{/}{t}}{{s}\text{/}{t}}} & (4)\end{matrix}$

where “s” is the length of the path of the electrode inthree-dimensional space (i.e., change in distance or position). Thechange in the ECI is calculated by sampling the ECI calculationsperformed by the ECU 32 (these calculations are described in greatdetail above) at a predetermined rate and then determining thedifference between a current calculation and the most recent previouscalculation, for example, that may be stored in a storage medium that ispart of accessible by the ECU 32. In another exemplary embodiment,however, the difference may be between a current calculation andmultiple previous calculations, or an average of previous calculations.

In an exemplary embodiment, the ECU 32 samples the calculated ECI every10 to 30 ms, and then calculates the change in the ECI over that timeinterval

$\left( {{i.e.},\frac{{ECI}}{t}} \right).$

It will be appreciated by those of ordinary skill in the art that theECI may be sampled at rates other than that described above, and thatsuch rates are provided for exemplary purposes only. For example, inanother exemplary embodiment, using techniques well known in the art,the sampling is timed or synchronized to coincide with the cardiac cycleso as to always sample at the same point in the cardiac cycle, therebyavoiding variances due to the cardiac cycle. In another exemplaryembodiment, the sampling of the ECI is dependent upon a triggeringevent, as opposed to being a defined time interval. For example, in oneexemplary embodiment, the sampling of the ECI is dependent upon thechange in the distance/position of the electrode 12 meeting a particularthreshold. More particularly, when the system 10 determines that theelectrode has moved a predetermined distance, the ECU 32 will thensample the ECI over the same period of time in which the electrode 12moved. Accordingly, it will be appreciated by those of ordinary skill inthe art that many different sampling rates and/or techniques may beemployed to determine the change in the ECI.

With respect to the change in the distance (or position/location) of theelectrode, this change may be calculated by the ECU 32 based on locationcoordinates provided to it by the system 30 (i.e., x, y, z coordinatesprovided by the mapping, visualization, and navigation system 30), ormay be calculated by the system 30 and then provided to the ECU 32. Aswith the change in ECI calculation, the change in distance or locationis determined by sampling the location coordinates of the electrode 12at a predetermined rate. From this, the change in distance over time

$\left( {{i.e.},\frac{s}{t}} \right)$

can be derived. In an exemplary embodiment, the location coordinates ofthe electrode 12 are sampled every 10 to 30 ms, and then the change inthe location is calculated over that time interval. It will beappreciated by those of ordinary skill in the art that thelocation/position of the electrode may be sampled at rates other thanthat described above, and that such rates are provided for exemplarypurposes only. For example, in another exemplary embodiment, usingtechniques well known in the art, the sampling is timed or synchronizedto coincide with the cardiac cycle so as to always sample at the samepoint in the cardiac cycle, thereby avoiding variances due to thecardiac cycle.

Once these two “change” calculations are complete, the ECU 32 is able tocalculate the ECIR by dividing the change in the ECI by the change inthe distance or location of the electrode 12

$\left( {{i.e.},\frac{{ECI}}{s}} \right).$

In an exemplary embodiment, the calculated ECIR is saved in a storagemedium that is accessible by the ECU 32.

Once the ECIR has been calculated, it may be used to assess, among otherthings, the proximity of the electrode 12 to the tissue 16. In anexemplary embodiment illustrated in FIG. 10, the ECIR is calculated in afirst step 102. In a second step 104, the calculated ECIR is evaluatedto determine whether the electrode 12 is within a predetermined distancefrom the tissue 16, in contact with the tissue 16, or further away fromthe tissue 16 than the predetermined distance.

More particularly, in a first substep 106 of step 104, a ECIR range 108is defined that correlates to a predetermined distance from the tissue16. In an exemplary embodiment provided for illustrative purposes only,the predetermined distance is 2 mm, and so the ECIR range 108 has afirst threshold value 110 that corresponds to 0 mm from the tissue 16(i.e., the electrode 12 is in contact with the tissue 16), and a secondthreshold value 112 that corresponds to a location that is 2 mm from thetissue 16. These thresholds may be set by either preprogramming theminto the ECU 32, or a user may manually input them into the ECU 32 usinga conventional I/O device.

In a second substep 114 of second step 104, the calculated ECIR iscompared to the predefined range 108 of ECIRs. Based on this comparison,the relative proximity of the electrode 12 is determined. Moreparticularly, if the calculated ECIR is within the range 108, then theelectrode 12 is deemed to be in “close proximity” of the tissue 16. Inthis particular embodiment, if the electrode 12 is within 0-2 mm of thetissue 16, it is deemed to be in “close proximity.” If the calculatedECIR falls below the first threshold value 110, then the electrode 12 isdeemed to be in contact with the tissue 16. Finally, if the calculatedECIR falls outside of the second threshold value 112, then the electrode12 is deemed to not be in close proximity of the tissue 16, but ratheris further away than the predetermined distance, which, in thisembodiment would mean that the electrode 12 is further than 2 mm fromthe tissue 16.

FIG. 11 is provided to show how the above described methodology may beapplied, and illustrates what a ECIR calculation may look like. Itshould be noted that the illustrated calculations are not based onactual testing or ECIR calculations made during an actual procedure, butrather are provided solely for illustrative purposes. In this particularexample, the ECIR range 108 is defined by a first threshold 110 having avalue of −6.0, which corresponds to 0 mm from the tissue 16, and asecond threshold 112 having a value of −0.5, which corresponds to 2 mmfrom the tissue 16. In this particular example, the predetermineddistance from the heart that is deemed to be “close proximity” is 0-2mm. It should be noted that the ECIR becomes negative as the tissue 16is approached because as the electrode 12 comes closer to the tissue 16,the ECI increases. Accordingly, the value representing the change in ECIis negative since a higher ECI is subtracted from a lower ECI.

As seen in FIG. 11, in this example, when the electrode 12 is more thanapproximately 2 mm away from the tissue 16, the ECIR is close to zero(0) and relatively stable, but more particularly hovering between −0.5and +0.5. This is partly because the further away from the tissue 16 theelectrode 12 is, the ECIR is less responsive. However, as the electrode12 approaches the tissue 16, the ECIR begins to decrease and becomesdramatically more dynamic. When electrode is approximately 2 mm away,the ECIR is around −0.5, which is the second threshold 112 of the ECIRrange 108. As the electrode 12 continues to get closer the tissue 12,and therefore in closer proximity thereto, the ECIR continues todecrease. In this example, when the electrode 12 reaches the tissue 16and makes initial contact, the ECIR is at −6.0, which is the firstthreshold 110 of the ECIR range 108. The ECIR then begins to stabilizeat a level around −7.0 that is much lower than the level when theelectrode is “far away” from the tissue (i.e., more than 2 mm) andoutside of the predetermined ECIR range 108.

Accordingly, by knowing the ECIR and comparing that rate to a predefinedECIR range representing a predetermined distance from the tissue 16, onecan easily determine whether the electrode 12 is in contact with, inclose proximity to, or far away from the tissue 16.

With reference to FIG. 12, another exemplary embodiment of a method forassessing the proximity using the ECIR will be described. In thisparticular embodiment, rather than comparing a calculated finite ECIR toa predefined range, the rate of change of the ECIR

$\left( {{i.e.},{\frac{}{t}\left( \frac{{ECI}}{s} \right)\mspace{14mu} {or}\mspace{14mu} \frac{^{2}{ECI}}{s^{2}}}} \right)$

is evaluated. It will be appreciated by those of ordinary skill in theart that the rate of change in the ECIR may be with respect to time orspace. Accordingly, both the temporal and spatial approaches will bedescribed below. By evaluating the rate of change in the ECIR, a morerobust and accurate proximity assessment can be performed.

More specifically, when the electrode 12 is within a predetermineddistance from the tissue 16, the rate of change in the ECIR, or changein the slope between ECIRs over a predetermined period of time, isgreater than when the electrode 12 is either in contact with or far awayfrom the tissue 16. (See FIG. 11, for example). Accordingly, it followsthat when the rate of change of the ECIR over a predetermined period oftime is within a certain range or equals particular rate that may bepreprogrammed into the ECU 32 or input by a user as described above, onemay be able to determine whether the electrode is within a predetermineddistance or in close proximity to the tissue. The methodology of thisparticular embodiment may carried out using either one of thecalculations represented by equation (5) or equation (6) below:

$\begin{matrix}{{{Rate}\mspace{14mu} {of}\mspace{14mu} {Change}\mspace{14mu} {of}\mspace{14mu} {ECIR}} = {\frac{}{t}\left( \frac{{ECI}}{s} \right)}} & (5) \\{{{Rate}\mspace{14mu} {of}\mspace{14mu} {Change}\mspace{14mu} {of}\mspace{14mu} {ECIR}} = {\frac{{\text{/}}{{t\left( {{{ECI}}\text{/}{s}} \right)}}}{{s}\text{/}{t}} = \frac{^{2}{ECI}}{s^{2}}}} & (6)\end{matrix}$

With reference to FIG. 12, in an exemplary embodiment, the rate ofchange in the ECIR may be determined by simply calculating the changebetween two or more ECIR calculations (i.e., equation (5) above). Insuch an embodiment, a storage medium 116 (i.e., memory 116) is providedto store a predetermined number of previously calculated ECIRs. Thememory 116 may be part of the ECU 32 (See FIG. 1), or may be a separatecomponent (or part of another component) that is accessible by the ECU32 such that the ECU 32 may retrieve the stored ECIRs. In an exemplaryembodiment, the ECU 32 is configured to access the memory 116 and tocalculate the rate of change of the ECIR or slope of a line drawnbetween a current or most recent ECIR calculation and one or more priorECIR calculations. If the rate of change or slope meets a predeterminedvalue or falls with a predetermined range, then the ECU 32 willrecognize that the ECIR has changed a certain amount, and therefore,that electrode 12 is within a certain distance of the tissue 16.

Accordingly, with reference to FIG. 12, in a first step 118 of thisparticular embodiment, a current ECIR is calculated. In a second step120, the ECU 32 accesses the memory 116 to retrieve one or morepreviously calculated ECIRs. In a third step 122, the rate of change orthe slope between the current ECIR and one or more previously calculatedECIRs is calculated. In a fourth step 124, the ECU 32 determines whetherthe electrode 12 is in close proximity to the tissue 16 based on therate of change in the ECIR.

In another exemplary embodiment of a methodology based on a rate ofchange in ECIR, small changes in the location or position of theelectrode 12, and therefore, the corresponding rate of change of thecorresponding ECIR, can be taken advantage of to obtain a substantiallycontinuous and robust assessment of proximity between the electrode 12and the tissue 16.

More particularly, perturbations can be induced or instigated in theposition of the electrode 12 either manually by a clinician or by way ofa robotic controller. These small changes in position of the electrode12 (e.g., on the order of 0.2 mm) can be measured by system 30, asdescribed above, and processed, at least in part, with the correspondingchange in the ECI and the change in position of the electrode 12 by theECU 32, for example, to calculate the rate of change of the ECIR. Thefrequency of these perturbations may be sufficiently high to allow forthe effective filtering or smoothing out of errors in the ECIRcalculations. This may be beneficial for a number of reasons, such as,for example, to resolve environmental events such as cardiac cyclemechanical events. In such an instance, the perturbation frequency wouldbe higher than the frequency of the cardiac cycle. In one exemplaryembodiment, the frequency of the perturbations is five to tenperturbations per second. Accordingly, the cardiac frequency may befiltered out of, or compensated for, in the calculations so as to smoothout any changes resulting during the cardiac cycle because of theconstant movement of the electrode.

Alternatively, if the perturbations occur less frequently, theinducement of the perturbations may be synchronized with or coordinatedto occur at one or more points in the cardiac cycle using knownmethodologies. By doing so, the filtering or smoothing effect describedabove may be carried out and also allow for the observation of proximitychanges as a result of catheter or electrode movement/manipulation orventilation, for example. Accordingly, the inducement of perturbationsand the resulting ECIR resulting from such perturbations can be used tofilter or smooth variation in signals resulting from cardiac cyclemechanical events, thereby providing a more robust system.

Accordingly, in this particular aspect of the invention, fastperturbations of the catheter, and therefore, the electrode, permitfrequent determinations of ECIR. At a separate and slower time scale,motions of the catheter and the electrode towards or away from thetissue permit a filtered derivative of ECIR. Changes over this longertime scale of the gradual distance toward or away from the tissue allowfor a good determination of a second spatial derivative of ECI

$\left( {{i.e.},{\frac{^{2}{ECI}}{s^{2}} = \frac{{\text{/}}{{t({ECIR})}}}{{s}\text{/}{t}}}} \right).$

Accordingly, this particular methodology represents a two time-scaleapproach (i.e., fast perturbations of the electrode 12 combined withslow movement of the electrode 12 towards the tissue 16). FIG. 13illustrates an exemplary representation of what the output of thismethodology looks like, which provides a sound representation ofproximity. Such a methodology results in a more robust discriminator ofproximity.

Whether the calculated ECIR is compared to a predetermined range ofECIRs, or the rate of change of the ECIR is evaluated to assess theproximity of the electrode 12 to the tissue 16, in an exemplaryembodiment, the system 10 may provide an indication to the clinicianmanipulating the catheter 14 or to a controller of a roboticallycontrolled device driving the catheter 14 that the electrode is in“close proximity” to the tissue 16. In one exemplary embodiment, the ECU32 is configured to generate a signal representative of an indicatorthat the electrode 12 is within the certain predetermined distance ofthe tissue 16 (e.g., 0-2 mm). In such an instance, this indicatorindicates that the electrode 12 is in close proximity to the tissue 16and allows the clinician or robotic controller to adjust its conductaccordingly (e.g., slow down the speed of approach). Such an indicatormay be visually displayed on the display 34 of the system in the samemanner described above with respect to the display of the ECI, may bedisplayed in graphical form, may be in the form of an audible warning,or may comprise any other known indicators. With respect to roboticapplications, the signal may be transmitted by the ECU 32 to acontroller from the robotic device, which receives and processes thesignal and then adjusts the operation of the robot as necessary. Inother exemplary embodiments, the ECU 32 may also provide indicators thatthe electrode 12 is far away from the tissue (i.e., further away than apredetermined distance), and/or that the electrode 12 is in contact withthe tissue.

Additionally, whether the ECI or the ECIR are used to determine orassess the proximity of the electrode to the tissue, in an exemplaryembodiment, the ECU 32 is programmed with a computer program (i.e.,software) encoded on a computer storage medium for assessing and/ordetermining the proximity of the electrode 12 to the tissue 16. In suchan embodiment, the program generally includes code for calculating a ECIresponsive to values for first and second components of the compleximpedance between the catheter electrode 12 and the tissue 16, and alsocode to process ECI in the various ways described above (i.e.,comparison of ECI to a predefined range, calculating ECIRs and comparingcalculated ECIR to predefined ranges, calculating rate of change in theECI and evaluating the same, and calculating rate of change in ECIR andevaluating the same, for example).

In accordance with another aspect of the invention, ECI (as well asother similar indices described in greater detail below) can be used toassess the formation of lesions in tissue—and more specifically, whethera particular area of tissue at a particular location has been changed(e.g., ablated)—as a result of an ablation procedure. In the context ofablation, in an exemplary embodiment, tissue may be deemed to be“changed,” for example, when a transmural lesion is formed in thetissue. Alternatively, tissue may be deemed to be unchanged, or at leastnot sufficiently changed, when no lesion is formed or a lesion isstarted but not fully formed in the tissue (e.g., the lesion is nottransmural). Tissue that has been changed, such as, for example, ablatedtissue or scar tissue, can have different electrical and functionalproperties than otherwise similar unchanged, or at least notsufficiently changed (e.g., unablated or not fully ablated), or virgintissue. As such, the capacitive and resistive properties of changedtissue are likewise different than that of otherwise similar unchangedtissue, and therefore, the ECI, for example, of changed tissue is alsodifferent than otherwise similar unchanged or insufficiently changedtissue. More specifically, the ECI of changed (e.g., ablated) tissue islower than that of otherwise similar unchanged or not sufficientlychanged (e.g., unablated or not fully ablated) tissue. Accordingly, inan exemplary embodiment, the catheter 14, and one or more electrodesthereof, such as, for example, electrode 12, in contact with an area oftissue is moved manually by a physician/clinician or through automationby a robotic system, for example, along or across the tissue (i.e.,along the longitudinal axis of the tissue or laterally relative to thelongitudinal axis) and ECI calculations are made by the ECU 32 in thesame manner described in great detail above. The ECI calculations maythen be evaluated and/or processed to enable a determination to be madeas to whether the particular area or portion of tissue in contact withthe electrode 12 has been changed (e.g., ablated) to such an extent tocause a change in the ECI. It may also be necessary to evaluate the ECIcalculation in light of contact readings, force readings, or some otherreadings to fully evaluate whether the tissue has changed.

For example, in an exemplary embodiment, it can be determined whether alesion line created during an ablation procedure is contiguous orwhether there are gaps therein that may or may not require additionalablation. This can be accomplished by dragging the electrode 12 alongthe perceived lesion line created during an ablation procedure, or backand forth across a perceived lesion line, and then processing/evaluatingECI calculations made at various points. The processing can determine ifa lesion is present in a number of ways. For example, the ECI valuescalculated for a particular location can be compared to a preset value(e.g., a value set by prior clinical experience, by an operator, or byvalues taken during the current procedure) to determine if a lesion ispresent. Likewise, the calculated ECI values could be compared to apreviously taken ECI value at that particular location. Similarly,changes in ECI over time and/or distance, or a rate of change in ECIvalues during an ablation procedure, could be considered. Alternatively,the ECU 32 can utilize multiple methods to identify a lesion.

With reference to FIG. 14a , an exemplary embodiment of a method ofECI-based lesion assessment is illustrated. In a first step 126, the ECU32 is programmed with a predetermined minimum ECI threshold 128 thatrepresents the minimum ECI level for which contact between the electrode12 and unchanged or not sufficiently changed (e.g., unablated or notfully ablated) tissue is attained. The ECU 32 may be preprogrammed withthe threshold 128 or a user may input the threshold 128 via aconventional I/O interface, thereby allowing the threshold 128 to bechanged. In a second step 130, while maintaining contact with thetissue, the electrode 12 is moved along or about an area of tissue thatwas, for example, subjected to an ablation procedure. In one exemplaryapplication, the area of tissue may be a lesion line created during anablation procedure, and a clinician/physician is dragging the electrode12 along or across the lesion line to determine whether there are gapsin the lesion line that may require additional ablation. It should benoted, however, that the present invention is not limited solely to thisparticular application. Rather, any number of lesion or scar tissueassessment applications (such as, for example, assessing lesion sizerather than gap detection, determining scar tissue borders, etc.) remainwithin the spirit and scope of the present invention.

As the electrode 12 is moved, in a third step 132, an ECI calculation ismade. Once the ECI calculation is made it can be used in any number ofways. In one exemplary embodiment, the ECU 32 is configured to comparethe ECI calculation to the ECI threshold 128, and in a fourth step 134,the ECU 32 makes such a comparison. If the calculated ECI value meets orexceeds the threshold 128, a determination can be made that the tissueat the particular location at which the ECI calculation was made has notchanged, or at least not sufficiently changed (e.g., the tissue has notbeen ablated or not fully ablated), since the calculated ECI is abovethe minimum ECI value. If, on the other hand, the calculated ECI valueis below the threshold 128, a determination can be made that the tissueat the location at which the ECI calculation was made has changed (e.g.,the tissue has been ablated), since the calculated ECI is below theminimum ECI value corresponding to contact with unchanged tissue.

In a fifth step 136, an indication is provided to theclinician/physician as to whether the tissue that is in contact with theelectrode 12 has changed. Accordingly, the ECU 32 is configured togenerate a signal representative of an indicator that the electrode 12is in contact with tissue that has or has not been changed (e.g.,ablated tissue if the change meets certain quantitative standards, orunablated or not fully ablated tissue if the tissue is unchanged or notsufficiently changed) based on the ECI calculation and comparison. Theindicator may take many forms. For example, the indicator may bedisplayed on the display monitor 34. Such a displayed indicator mayinclude, for exemplary purposes only, displaying the actual ECIcalculation on the monitor, a graphical representation, or theillumination/de-illumination or changing color of a beacon on themonitor. In other embodiments, the indicator may take the form of anaudible alert, a visible indication on the catheter handle, hapticfeedback, or any other indicators known in the art. In a robotics-basedsystem, the indicator may take the form of a signal provided to arobotic controller. In still other embodiments the feedback can take theform of an indication placed on an anatomical map that is displayed onthe display monitor 34, for example, an electroanatomical map of thesort generated by the St. Jude Medical EnSite™ ElectroanatomicalModeling System, the Biosense Webster Carto™ System, a fluoroscopysystem, an MRI image, a CT scan, a magnetic location system such as thegMPS system from Mediguide Ltd., or another image of the subject tissuedisplayed on the display monitor 34 to indicate what portions of thetissue have been changed, and which portions have not. In an exemplaryembodiment, a display monitor, such as, for example, the display monitor34, may be configured to display an image or map thereon that mayprovide a visual display of the effectiveness of an ablation procedureas set forth in U.S. patent application Ser. No. 12/622,626 entitled“System and Method for Assessing Effective Delivery of AblationTherapy,” filed Nov. 20, 2009 in the name of Deno, et al., which isincorporated herein by reference in its entirety. The above describedprocess is then repeated as the electrode continues to move.

FIG. 14b depicts another exemplary embodiment of the method illustratedin FIG. 14a in which steps relating to an ablation procedure areincluded. For example, in a sixth step 137 a determination is made as towhether the portion of the tissue at the particular location that isbeing evaluated (i.e., the tissue that electrode 12 is in contact with)has been changed (e.g., ablated). In an exemplary embodiment, theparticular location of the portion of the tissue is determined using themapping, visualization, and navigation system 30.

If the tissue has been changed, the calculated ECI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. In a seventh step 138, system 10 then determines whetherthe ablation procedure can be ended. If “yes,” then the ablationprocedure is stopped. If “no,” then the process begins again at secondstep 130.

If the tissue has not been changed, or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller, or othercomponent of the system, can make such a determination. If tissue shouldbe ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter 14 to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 130.

If the tissue should not be ablated, then the ECI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. The system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at second step 130.

In another exemplary embodiment, rather than comparing a calculated ECIwith an ECI threshold, the change in the ECI over either time or space(distance) is evaluated. In an exemplary embodiment, the change in ECIover a predetermined amount of time

$\left( {{i.e.},\frac{{ECI}}{t}} \right)$

is determined and evaluated. FIG. 15a illustrates an exemplaryembodiment of a methodology based on change in ECI over time.

In a first step 139, an ECI calculation for a particular area of thetissue 16 is made and then stored in a storage medium, such as, forexample, memory 92/116. In a second step 140, the ECU 32 calculatesanother ECI after a predetermined period of time has elapsed. Thiscalculated ECI may correspond to the same area of the tissue 16 or adifferent area of the tissue 16. The ECU 32 may be programmed with thetime interval or sampling rate that constitutes the predetermined periodof time, or it may be entered by the user via a conventional I/Ointerface. In a third step 142, the ECU 32 compares the previouslystored ECI calculation with the current ECI calculation and determinesif there is a change, and if so, the degree of such a change. No changein ECI is indicative of the electrode remaining in contact with the sametype of tissue (i.e., the electrode has not moved from unchanged or notsufficiently changed (e.g., unablated or not fully ablated) tissue tochanged (e.g., ablated) tissue, or vice versa, and therefore, there isno appreciable change in ECI). A “positive” change value is indicativeof the electrode 12 moving from contact with unchanged or notsufficiently changed tissue to changed tissue (i.e., higher ECI forunchanged or insufficiently changed (e.g., unablated or not fullyablated) tissue compared to lower ECI for changed (e.g., ablated) tissueresults in a positive number). Finally, a “negative” change value isindicative of the electrode 12 moving from contact with changed tissueto unchanged or insufficiently changed tissue (i.e., lower ECI forchanged (e.g., ablated) tissue compared to higher ECI for unchanged orinsufficiently changed (e.g., unablated or not fully ablated) tissueresults in a negative number).

In an instance where the comparison of the ECI calculations results in achange—whether positive or negative—in an exemplary embodiment, thedegree of change may be taken into account such that the change mustmeet a predetermined threshold to be considered a change in contact fromchanged to unchanged or insufficiently changed tissue (or vice versa).This allows for some change in ECI without necessarily indicating achange in the tissue.

With continued reference to FIG. 15a , in a fourth step 144, anindication is provided to the clinician/physician, or to a roboticcontroller in a robotics-based system, as to whether the portion of thetissue that is presently in contact with the electrode 12 is changed(e.g., ablated) or unchanged or not sufficiently changed (e.g.,unablated or not fully ablated) tissue. Accordingly, the ECU 32 isconfigured to generate signal representative of an indicator of the typeof tissue the electrode 12 is in contact with based on the comparison ofECI calculations. The description set forth in great detail aboverelating to the generation and/or provision of indicators applies herewith equal weight, and therefore, will not be repeated. This processrepeats itself as the electrode 12 continues to move. Accordingly, eachECI calculation is saved in the memory 92/116 so that it may be comparedto one or more subsequent ECI calculations.

FIG. 15b depicts another exemplary embodiment of the method illustratedin FIG. 15a in which steps relating to an ablation procedure areincluded. For example, in a fifth step 145, a determination is made asto whether the tissue at the particular location that is being evaluated(i.e., the tissue that electrode 12 is in contact with) has been changed(e.g., ablated). If it has, the calculated ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.In a sixth step 146, system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 139.

If the tissue has not been changed, or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller can makesuch a determination. If tissue should be ablated, ablative energy canbe applied to the tissue at that particular location. Accordingly, thephysician/clinician may move the catheter 14 to the particular locationrequiring ablation and then cause the ablative energy to be applied.Alternatively, in a robotic application, the robotic controller maycause the catheter 14 to move to the particular location requiringablation and then cause the ablative energy to be applied. In such anembodiment, the system 30 may be used by the robotic controller todetermine where the catheter 14 is and where it needs to go, as well asto assist in the direction of the movement of the catheter 14 to thedesired location. The process may then proceed starting at step 139. Ifthe tissue should not be ablated, then the ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.The system 10 then determines, whether the ablation procedure can beended. If “yes,” then the ablation procedure is stopped. If “no,” thenthe process begins again at step 139.

In another exemplary embodiment, besides comparing a calculated ECI withan ECI threshold or evaluating the change in the ECI over apredetermined time interval, the change in the ECI over a predeterminedspace or surface distance

$\left( {{i.e.},\frac{{ECI}}{s}} \right)$

is determined and evaluated. FIG. 16a illustrates an exemplaryembodiment of a methodology based on change in ECI over distance orspace.

In a first step 147, an ECI calculation is made for a particular area ofthe tissue 16 and then stored in a storage medium, such as, for example,memory 92/116. In a second step 148, the ECU 32 calculates another ECIcalculation after it is determined that the electrode 12 has traveled apredetermined distance either longitudinally along the longitudinal axisof a lesion, or laterally relative to the longitudinal axis to anotherarea of the tissue 16. In an exemplary embodiment, the ECU 32 isconfigured to receive location data (such as x, y, z coordinates) fromthe mapping, visualization, and navigation system 30 and to calculatechange in distance relative to prior stored location data also receivedfrom system 30. In another exemplary embodiment, system 30 is configuredto process the location data to calculate a change in distance and toprovide the change to the ECU 32 for it determine whether thepredetermined sampling distance has been met. Accordingly, thecalculation may be triggered when the electrode moves a certaindistance. The predetermined distance may be programmed into the ECU 32or may be entered by a user via a conventional I/O interface.

In a third step 150, the ECU 32 compares the previously stored ECIcalculation with the current ECI calculation and determines if there isa change, and if so, the degree of such a change. No change in ECI isindicative of the electrode remaining in contact with either changed orunchanged, or at least not sufficiently changed tissue (i.e., theelectrode has not moved from unchanged or not sufficiently changed(e.g., unablated or not fully ablated) tissue to changed (e.g., ablated)tissue, or vice versa, and therefore, there is no appreciable change inECI). A “positive” change value is indicative of the electrode 12 movingfrom contact with unchanged or insufficiently changed tissue to changedtissue (i.e., higher ECI for unchanged or not sufficiently changed(e.g., unablated or not fully ablated) tissue compared to lower ECI forchanged (e.g., ablated)tissue results in a positive number). Finally, a“negative” change value is indicative of the electrode 12 moving fromcontact with changed tissue to unchanged, or at least not sufficientlychanged tissue (i.e., lower ECI for changed (e.g., ablated) tissuecompared to higher ECI for unchanged or insufficiently changed (e.g.,unablated or not fully ablated) tissue results in a negative number).

In an instance where the comparison of the ECI calculations results in achange—whether positive or negative—in an exemplary embodiment thedegree of change may be taken into account such that the change mustmeet a predetermined threshold to be considered a change in contact fromchanged to unchanged, or at least not sufficiently changed, tissue (orvice versa). This allows for some change in ECI without necessarilyindicating a change in the tissue.

With continued reference to FIG. 16a , in a fourth step 152, anindication is provided to the clinician/physician, or to a roboticcontroller in a robotics-based system, as to whether the portion of thetissue that is presently in contact with the electrode 12 hassufficiently changed (e.g., is ablated) or is unchanged orinsufficiently changed (e.g., is unablated or not fully ablated).Accordingly, depending on the result of the evaluation of the ECIvalues, the ECU 32 is configured to generate signal representative of anindicator of the type of tissue the electrode 12 is in contact with(e.g., changed (e.g., ablated) or unchanged/insufficiently changed(e.g., unablated or not fully ablated). The description set forth ingreat detail above relating to the generation and/or provision ofindicators applies here with equal weight, and therefore, will not berepeated. This process repeats itself as the electrode 12 continues tomove. Accordingly, each ECI calculation is saved in the memory 92/116 sothat it may be compared to one or more subsequent ECI calculations.

FIG. 16b depicts another exemplary embodiment of the method illustratedin FIG. 16a in which steps relating to an ablation procedure areincluded. For example, in a fifth step 153, a determination is made asto whether the tissue at the particular location that is being evaluated(i.e., the tissue that electrode 12 is in contact with) has been changed(e.g., ablated). If it has, the calculated ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.In a sixth step 154, system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 147.

If the tissue has not been changed, or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller can makesuch a determination. If the tissue should be ablated, ablative energycan be applied to the tissue at that particular location. Accordingly,the physician/clinician may move the catheter 14 to the particularlocation requiring ablation and then cause the ablative energy to beapplied. Alternatively, in a robotic application, the robotic controllermay cause the catheter 14 to move to the particular location requiringablation and then cause the ablative energy to be applied. In such anembodiment, the system 30 may be used by the robotic controller todetermine where the catheter 14 is and where it needs to go, as well asto assist in the direction of the movement of the catheter 14 to thedesired location. The process may then proceed starting at step 147. Ifthe tissue should not be ablated, then the ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.The system 10 then determines whether the ablation procedure can beended. If “yes,” then the ablation procedure is stopped. If “no,” thenthe process begins again at step 147.

In another exemplary embodiment, two or more ECI calculations for tissueat a particular location at two different points in time can beevaluated to determine whether the tissue at that particular locationhas been changed (e.g., ablated). More specifically, and with referenceto FIG. 17a , in a first step 155, an ECI calculation is made for tissueat a particular location. In a second step 156, the ECI calculation andthe corresponding location—which may be acquired from the mapping,visualization and navigation system 30—are saved in a storage medium,such as, for example and without limitation, the memory 92/116.

As the electrode 12 moves, a number of ECI calculations can be made.Once the procedure has been completed, in a third step 158, theelectrode 12 can be brought back over the area that was to be ablated todetermine if tissue at a particular location was, in fact, changed(e.g., ablated). In a fourth step 160, as the electrode visits eachlocation for which a prior ECI calculation was made, another ECIcalculation is made. In a fifth step 162, the ECU 32 accesses the priorECI calculation that corresponds to the particular location, andcompares the ECI calculations corresponding to the particular locationto determine whether the ECI has changed. As described in greater detailabove, whether the ECI value, or the change therein, meets, exceeds, orfalls below a predetermined threshold, the ECU 32 is able to determinewhether the tissue at that particular location has been changed (e.g.,ablated). This process then continues as the electrode 12 continues tomove along or about a perceived lesion line or area, or as long as theclinician/physician desires.

In an exemplary embodiment, in a sixth step 164, the ECU 32 may beconfigured to provide an indication of the respective ECI values, whicha user may take into consideration and make a determination as towhether the tissue is changed (e.g., ablated) or unchanged, or at leastnot sufficiently changed (e.g., unablated or not fully ablated), and/orwhether the tissue that the electrode is or was in contact with ischanged or unchanged, or at least not sufficiently changed (e.g.,unablated or not fully ablated) tissue. In either instance, thedescription set forth in great detail above relating to the generationand/or provision of indicators applies here with equal weight, andtherefore, will not be repeated. Additionally, the description set forthabove relating to the tolerances and/or the substantiality of the changein ECI applies here with equal force.

FIG. 17b depicts another exemplary embodiment of the method illustratedin FIG. 17a in which steps relating to an ablation procedure areincluded. For example, in a seventh step 165, a determination is made asto whether the tissue at the particular location that is being evaluated(i.e., the tissue that electrode 12 is in contact with) has been changed(e.g., ablated). If it has, the calculated ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.In an eighth step 166, the system 10 then determines whether theablation procedure can be ended. If “yes,” then the ablation procedureis stopped. If “no,” then the process begins again at step 155.

If the tissue has not been changed, or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller can makesuch a determination. If tissue should be ablated, ablation energy canbe applied to the tissue at that particular location. Accordingly, thephysician/clinician may move the catheter 14 to the particular locationrequiring ablation and then cause the ablative energy to be applied.Alternatively, in a robotic application, the robotic controller maycause the catheter 14 to move to the particular location requiringablation and then cause the ablative energy to be applied. In such anembodiment, the system 30 may be used by the robotic controller todetermine where the catheter 14 is and where it needs to go, as well asto assist in the direction of the movement of the catheter 14 to thedesired location. The process may then proceed starting at step 155. Ifthe tissue should not be ablated, then the ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.The system 10 then determines whether the ablation procedure can beended. If “yes,” then the ablation procedure is stopped. If “no,” thenthe process begins again at step 155.

In another exemplary embodiment, rather than evaluating the finite orraw ECI calculation or determining a change in two ECI calculations, therate of change of the ECI or the slope of a line between at least twoECI calculations over a predetermined amount of time

$\left( {{i.e.},\frac{^{2}{ECI}}{t^{2}}} \right)$

is determined and used to assess lesion formation. More particularly,when the electrode 12 moves from tissue that has been changed (e.g.,ablated) to tissue that has not been changed or at least notsufficiently changed (e.g., unablated or not fully ablated), the rate ofchange or the change in the slope over a predetermined amount of time ismost evident. In other words, if the electrode 12 remains in contactwith either changed (e.g., ablated) or unchanged/insufficiently changed(e.g., unablated or not fully ablated) tissue, respectively, the rate ofchange in the ECI may not be appreciable. However, when the electrode 12moves from tissue that has been changed to tissue that has not beenchanged, or at least not sufficiently changed, or vice versa, the rateof change in the ECI may be appreciable. Thus, if the rate of changeover a predetermined period of time meets, exceeds, or falls below(depending on the circumstances) a predetermined threshold value, thenone is able to determine what type of tissue with which the electrode 12is currently in contact. Accordingly, the rate of change in ECI or thechange in the slope over a predetermined period of time can be useful inassessing lesion formation.

FIG. 18a illustrates one exemplary embodiment of a methodology that usesthe rate of change of the ECI. In this embodiment, the memory 92/116stores a predetermined number of previously calculated ECI calculations.As described above, the memory 92/116 may be part of the ECU 32 or maybe a separate and distinct component that is accessible by the ECU 32such that the ECU 32 may retrieve the stored ECIs. In an exemplaryembodiment, the ECU 32 is configured to access the memory 92/116 and tocalculate the rate of change in the ECI or the slope of a line drawnbetween a current or most recent ECI calculation and one or morepreviously calculated ECIs. Depending on if the rate of change meets,exceeds, or falls below a predetermined threshold that is programmedinto ECU 32, the ECU 32 may be configured to recognize that theelectrode 12 is in contact with changed (e.g., ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue, or may simply provide the rate of change to a user for the userto determine the type of tissue with which the electrode is in contact.

Accordingly, with continued reference to FIG. 18a , in a first step 168,a current ECI is calculated and may be stored in the memory 92/116. In asecond step 170, the ECU 32 accesses the memory 92/116 to retrieve oneor more previously calculated ECIs. In a third step 172, the rate ofchange or slope between the current ECI and the one or more previouslycalculated ECIs stored in the memory 92/116 is calculated. In a fourthstep 174, the ECU 32 determines whether the electrode 12 is in contactwith tissue that has been changed (e.g., ablated) or tissue that has notbeen changed, or at least not sufficiently changed (e.g., unablated ornot fully ablated) based on the calculated rate of change. In anexemplary embodiment, in a fifth step 176, an indication may be providedto the clinician/physician as to what type of tissue with which theelectrode 12 is currently in contact. Accordingly, the ECU 32 may befurther configured to generate a signal representative of an indicatorcorresponding to the type of tissue with which the electrode 12 is incontact. The description set forth above in great detail relating to thegeneration and/or provision of indicators applies here with equalweight, and therefore, will not be repeated.

FIG. 18b depicts another exemplary embodiment of the method illustratedin FIG. 18a in which steps relating to an ablation procedure areincluded. For example, in a sixth step 178, a determination is made asto whether the tissue at the particular location that is being evaluated(i.e., the tissue that electrode 12 is in contact with) has been changed(e.g., ablated). If it has, the calculated ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.In a seventh step 180, the system 10 then determines whether theablation procedure can be ended. If “yes,” then the ablation procedureis stopped. If “no,” then the process begins again at step 168.

If the tissue has not been changed, or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated orreablated. Alternatively, in a robotic application, a robotic controllercan make such a determination. If tissue should be ablated, ablativeenergy can be applied to the tissue at that particular location.Accordingly, the physician/clinician may move the catheter 14 to theparticular location requiring ablation and then cause the ablativeenergy to be applied. Alternatively, in a robotic application, therobotic controller may cause the catheter 14 to move to the particularlocation requiring ablation and to then cause the ablative energy to beapplied. In such an embodiment, the system 30 may be used by the roboticcontroller to determine where the catheter 14 is and where it needs togo, as well as to assist in the direction of the movement of thecatheter 14 to the desired location. The process may then proceedstarting at step 168. If the tissue should not be ablated, then the ECIand ablation information may be stored in a storage medium, such as, forexample, memory 92/116. The system 10 then determines whether theablation procedure can be ended. If “yes,” then the ablation procedureis stopped. If “no,” then the process begins again at step 168.

In another exemplary embodiment, rather than evaluating static or rawECI calculations, or the rate of change in such calculations, ECI may beused, in part, to calculate an ECI rate (ECIR). The ECIR can be used inlesion assessment. In an exemplary embodiment, the ECU 32 is configuredto calculate the ECIR, however, the present invention is not meant to beso limited. Rather, other processors or components may be employed toperform the calculation.

In simple terms, the ECIR is calculated by dividing the change in ECIover a predetermined amount of time by the change in the distance orposition of the electrode 12 over the same predetermined amount of time.More specifically, the ECIR is calculated using equation (4) above. Asdescribed above, the change in the ECI is calculated by sampling the ECIcalculations performed by the ECU 32 at a predetermined rate and thendetermining the difference between a current calculation and the mostrecent previous calculation, for example, that may be stored in thememory 92/116. In another exemplary embodiment, the difference may bebetween a current calculation and multiple previous calculations, or anaverage of previous calculations.

In an exemplary embodiment, the ECU 32 samples the calculated ECI at apredetermined sampling rate, and then calculates the change in the ECIover that time interval. It will be appreciated by those of ordinaryskill in the art that the ECI may be sampled at any number of timeintervals or rates. For example, in one embodiment using knowntechniques, the sampling is timed or synchronized to coincide with thecardiac cycle of the patient's heart so as to always sample at the samepoint in the cardiac cycle. In another embodiment, the sampling of theECI is dependent upon a triggering event rather than a defined timeinterval. For instance, the sampling of the ECI may be dependent uponthe change in the distance/position of the electrode 12 meeting apredetermined threshold. More specifically, when it is determined thatthe electrode 12 has moved a predetermined distance, the ECU 32 willsample the ECI over the time interval it took the electrode 12 to movethe predetermined distance. Accordingly, it will be appreciated by thoseof ordinary skill in the art that many different sampling rates and/ortechniques may be used to determine the change in ECI.

With respect to the change in distance/location of the electrode, asdescribed above this change may be calculated by the ECU 32 based onlocation coordinates provided to it by the system 30, or may becalculated by the system 30 and then provided to the ECU 32. As with thechange in ECI, the change in distance or location is determined bysampling the location coordinates of the electrode 12 at a predeterminedsampling rate. From this, the change in distance over time can bederived. As with the sampling of the ECI calculations, the locationcoordinates of the electrode 12 are sampled at a predetermined samplingrate and then the change in the location is calculated over that timeinterval. It will be appreciated by those of ordinary skill in the artthat the location/position may be sampled at various rates and usingvarious techniques (e.g., synchronization with cardiac cycle).Accordingly, the present invention is not limited one particularsampling rate/technique.

Once the two “change” calculations have been made, the ECU 32 is able tocalculate the ECIR by dividing the change in the ECI by the change inthe distance or location of the electrode 12. In an exemplaryembodiment, the calculated ECIR is stored in a storage medium, such as,for example, memory 92/116, that is accessible by the ECU 32.

Once the ECIR has been calculated, it may be used to assess, among otherthings, whether the electrode 12 is in contact with tissue that has beenchanged (e.g., ablated) or tissue that has not changed, or at least hasnot sufficiently changed (e.g., unablated or not fully ablated). In anexemplary embodiment illustrated in FIG. 19a , the ECIR is calculated ina first step 182 by dividing the change in ECI by the change indistance. In a second step 184, the calculated ECIR is evaluated todetermine whether the calculated ECIR meets, exceeds, or falls below apredefined threshold value. Depending on where the calculated ECIR fallswith respect to the threshold, a determination can be made as to whattype of tissue with which the electrode 12 is in contact.

More particularly, in a first substep 186 of step 184, an ECIR thresholdis defined. This threshold may be set by either preprogramming it intothe ECU 32, or a user may manually input it into the ECU 32 using aconventional I/O interface.

In a second substep 188 of second step 184, the calculated ECIR iscompared to the predefined threshold. Based on this comparison, thedetermination is made as to what type of tissue the electrode 12 iscontacting (e.g., changed (e.g., ablated) or unchanged/insufficientlychanged (e.g., unablated or not fully ablated), for example) or fromwhat type of tissue the electrode has traveled. In an exemplaryembodiment, in a third step 190, the ECU 32 may be configured to providean indication as to the value of the ECIR, which a user may take intoconsideration and make a determination as to whether the tissue has beenchanged (e.g., ablated) or unchanged/insufficiently changed (e.g.,unablated or not fully ablated), and/or whether the tissue that theelectrode is or was in contact with has been changed orunchanged/insufficiently changed (e.g., ablated or unablated/not fullyablated tissue). The description set forth in great detail aboverelating to the generation and/or provision of indicators applies herewith equal force, and therefore, will not be repeated.

FIG. 19b depicts another exemplary embodiment of the method illustratedin FIG. 19a in which steps relating to an ablation procedure areincluded. For example, in a fourth step 192, a determination is made asto whether the tissue at the particular location that is being evaluated(i.e., the tissue that electrode 12 is in contact with) has been changed(e.g., ablated). If it has, the calculated ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.In a fifth step 194, the system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 182.

If the tissue has not been changed, or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller can makesuch a determination. If tissue should be ablated, ablative energy canbe applied to the tissue at that particular location. Accordingly, thephysician/clinician may move the catheter 14 to the particular locationrequiring ablation and then cause the ablative energy to be applied.Alternatively, in a robotic application, the robotic controller maycause the catheter 14 to move to the particular location requiringablation and to then cause the ablative energy to be applied. In such anembodiment, the system 30 may be used by the robotic controller todetermine where the catheter 14 is and where it needs to go, as well asto assist in the direction of the movement of the catheter 14 to thedesired location. The process may then proceed starting at step 182. Ifthe tissue should not be ablated, then the ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.The system 10 then determines whether the ablation procedure can beended. If “yes,” then the ablation procedure is stopped. If “no,” thenthe process begins again at step 182.

In any of the embodiments above, there are several variables that mayhave an impact on the calculation of the ECI. For example, the amount ofcontact force or contact pressure applied to the electrode against thetissue, the particular type of tissue being evaluated (i.e., differenttypes of cardiac tissue, for example), the temperature of the tissue orchange in temperature of the tissue, the degree of heating of thetissue, the depth of tissue heated, the volume of tissue heated, thesaline flow rate through the catheter, the blood flow rate across thecatheter, and the like may individually or collectively cause an impactin the ECI calculation. Therefore, in certain embodiments, thesevariables can be taken into account in the calculation.

Accordingly, in an exemplary embodiment, offsets may be used to eitherincrease or decrease the calculated ECI to a Corrected ECI (“CECI”) toaccount for one or more variables. These offsets perform a scalingfunction to ensure that it is the actual ECI of the tissue that is beingassessed or evaluated rather than an ECI influenced by one or morevariables. These offsets may be stored, for example, in the memory92/116 such that the ECU 32 can access them when appropriate. Theseoffsets may be arranged in the form of a look-up table or in anotherequivalent structure or manner and correlated with particular forcemagnitudes, temperatures, tissue type, etc. Accordingly, when making aCECI calculation, the ECU 32 is configured to receive one or more inputscorresponding to one or more variables, and to then evaluate or processthe CECI calculation accordingly.

For example, the ECU 32 may be configured to receive a force measurementfrom a force gauge that may be mounted proximate the electrode 12 orotherwise associated therewith, representing the amount of contact forcebeing applied to the tissue. The ECU 32 may be configured to access alook up table stored in the memory 92/116, in ECU 32 (or elsewhere inthe system 10) that correlates one or more force measurements withcorresponding CECI offsets. Likewise, the ECU 32 may be configured tocalculate a corresponding CECI offset from a predetermined relationshipbetween the degree of force and the desired CECI offset. Thus, when theECU 32 makes a CECI calculation, it can look up the force measurement inthe table, acquire the appropriate offset, and then add or subtract theoffset from the CECI calculation. This permits ECI calculations, amongother things, to be compared with each other regardless of the amount offorce being applied by the electrode 12 against the tissue at anyparticular time.

Likewise, the ECU 32 may be configured to receive a pressure measurementfrom a pressure or force gauge that may be mounted proximate to theelectrode 12 or otherwise associated therewith, representing the amountof contact pressure being applied to the tissue. The ECU 32 may beconfigured to access a lookup table stored in the memory 92/116, in ECU32 (or elsewhere in the system 10) that correlates one or more pressureor force measurements with corresponding CECI offsets. Likewise, the ECU32 may be configured to calculate a corresponding CECI offset from apredetermined relationship between the pressure and the desired CECIoffset. If the measurement is a force measurement, it can be correctedbased on the characteristics of the catheter used into a pressuremeasurement. Thus, when the ECU 32 makes a CECI calculation, it can lookup the pressure measurement in the table, acquire the appropriateoffset, and then add or subtract the offset from the ECI calculation.This permits CECI calculations, among other things, to be compared witheach other regardless of the amount of pressure being applied by theelectrode 12 against the tissue at any particular time.

This same process may be used for temperature measurements, and othervariables, such as, for example, saline flow rate through the catheter,blood flow rate across the catheter, and other parameters that couldaffect ECI though coupling to the tissue has not changed. For example,the system may either directly measure a temperature of the tissue or itmay receive a temperature input from an outside source. The temperatureinput can be electrode temperature, a tissue temperature, or anothertype of measurement. As with force or pressure, this temperature inputis sent to the ECU 32, which is configured to access a lookup tablestored in the memory 92/116, in ECU 32 (or elsewhere in the system 10)that correlates one or more temperature or heating measurements withcorresponding CECI offsets. Likewise, the ECU 32 may be configured tocalculate a corresponding CECI offset from a predetermined relationshipbetween the temperature and the desired CECI offset. This process mayalso be used for evaluating different types of tissue. In such anembodiment, the ECU 32 is configured to receive an input to allow theECU 32 to recognize the type of tissue being evaluated. In an exemplaryembodiment, the user is permitted to indicate the tissue type by way ofa conventional I/O interface. Accordingly, different variables may betaken into account in the ECI calculations.

One challenge in assessing lesions and/or determining whether tissue hasbeen ablated lies in the fact that the ECI will change if contactbetween the electrode 12 and the tissue changes. Accordingly, a changein the ECI alone may not always be sufficiently indicative of tissuehaving been changed (e.g., ablated). For example, the ECI changes ifthere is a loss of contact between the electrode 12 and the tissue.Similarly, ECI changes as electrode 12 moves from contact with unchangedor insufficiently changed (e.g., unablated or not fully ablated) tochanged (e.g., ablated) tissue. As such, the change in ECI resultingfrom loss of contact may pose a challenge to providing an indicationthat the tissue at that particular location has been changed (e.g.,ablated). One way to address or overcome such a challenge is bymeasuring either contact force or contact pressure (or both).Accordingly, in order to determine whether the change in the ECI is dueto loss of contact or rather change in the tissue, the ECI and the forceand/or the pressure are evaluated together. Thus, in another exemplaryembodiment, rather than evaluating the ECI alone for lesion assessment,the calculated ECI and force measurements may be evaluated together todetermine or assess whether tissue has been changed (e.g., ablated), andsuch an evaluation may be made in substantially real-time.

For example, prior to the electrode 12 contacting tissue, the force(and/or the pressure) and the ECI are both relatively low. Once contactis made, the force (and/or the pressure) and the ECI increase. Whenablation commences, the force may not dramatically change, but the ECImay change. Accordingly, at the divergence between the force and theECI, it can be determined that the tissue at that particular locationhas been or is being ablated, as opposed to a change in the ECI asresult of loss of contact. Therefore, both the force and ECI can beevaluated and monitored by the ECU 32, and then a determination can bemade based on the changes in each as to whether tissue at a particularlocation has been changed (e.g., ablated) or not.

FIG. 20a illustrates an exemplary embodiment of this methodology. In afirst step 196, an ECI calculation is made and compared to one or morestored previously calculated ECIs. In a second step 198, a forcemeasurement is made and compared to one or more previously acquiredforce measurements or to a lookup table. The ECU 32 may be configured toreceive and compare the force measurements, or alternatively, the changein force may be calculated elsewhere in the system 10 and provided tothe ECU 32. In either instance, in a third step 200, the change in theECI and the change in the force are processed with each other and thenthe ECU 32 determines whether the ECI and force have diverged. If so,the ECU 32 recognizes that there has been a change in the type of tissue(i.e., changed (e.g., ablated) or unchanged/insufficiently changed(e.g., unablated or not fully ablated)) with which the electrode 12 isin contact. As described above, in a fourth step 202, an indicator maybe generated and/or displayed to communicate the type of tissue. Thedescription set forth in great detail above relating to the generationand/or provision of indicators applies here with equal force, andtherefore, will not be repeated.

FIG. 20b depicts another exemplary embodiment of the method illustratedin FIG. 20a in which steps relating to an ablation procedure areincluded. For example, in a fifth step 204, a determination is made asto whether the tissue at the particular location that is being evaluated(i.e., the tissue that electrode 12 is in contact with) has been changed(e.g., ablated). If it has, the calculated ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.In a sixth step 206, the system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 196.

If the tissue has not been changed or at least not sufficiently changed(e.g., the tissue is unablated or not fully ablated), then thephysician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller can makesuch a determination. If tissue should be ablated, ablation energy canbe applied to the tissue at that particular location. Accordingly, thephysician/clinician may move the catheter 14 to the particular locationrequiring ablation and then cause the ablative energy to be applied.Alternatively, in a robotic application, the robotic controller maycause the catheter 14 to move to the particular location requiringablation and to then cause the ablative energy to be applied. In such anembodiment, the system 30 may be used by the robotic controller todetermine where the catheter 14 is and where it needs to go, as well asto assist in the direction of the movement of the catheter 14 to thedesired location. The process may then proceed starting at step 196. Ifthe tissue should not be ablated, then the ECI and ablation informationmay be stored in a storage medium, such as, for example, memory 92/116.The system 10 then determines whether the ablation procedure can beended. If “yes,” then the ablation procedure is stopped. If “no,” thenthe process begins again at step 196.

It should be noted that the above described methodology may be employedtaking into account variables other than or in addition to force, suchas, for example, pressure. In such an instance, the same steps abovewould apply with equal force, with the exception that the measurementsand comparisons would relate to pressure rather than force. Accordingly,the methodology will not be repeated here.

In accordance with another aspect of the invention, indices other thanECI, such as, for example, an ablation lesion index (ALI), may becalculated and evaluated to allow for the assessment of lesions. Suchindices may take into account the complex impedance, or the componentsthereof (i.e., the resistance “R” and the reactance “X”, for example),as well as variables such as temperature, pressure, contact force,saline flow rate through the catheter, blood flow rate across thecatheter, and/or other parameters that could affect ALI though couplingto the tissue has not changed. As with ECI, in an exemplary embodiment,these indices may be displayed on a display in any number of ways orformats, or otherwise used to provide information in a useful format toa clinician/physician or robotic controller to allow for, or aid in, theassessment of lesion formation.

In an exemplary embodiment, an ALI derived from ECI is defined andcalculated. In such an embodiment, the ALI calculation takes intoaccount ECI as well as various confounding variables such as, forexample, contact force and tissue temperature. In other exemplaryembodiments, additional confounding variables such as, for example,trabeculation, may be taken into account. As will be described ingreater detail below, the ALI can be specifically used for determiningablation lesion changes induced in tissue such that one can determinewhether tissue has been changed (e.g., ablated), and if so, assess thequality or extent of the formed lesion, as well as to determine lesionvolume growth. Since temperature is taken into consideration, such anindex would find particular applicability in real-time assessment oflesions as they are created during an ablation procedure. In anembodiment in which the ALI is calculated taking into accounttemperature and force, the catheter 14 would include temperature andforce sensors mounted thereon to obtain measurements for the temperatureand force variables. As will be seen below, trabeculation cannot bedirectly measured, and so this variable can be determined by evaluatingother confounding variables.

Accordingly, in an exemplary embodiment in which the ALI is used in theassessment of lesion formation, the ECU 32 may be configured to receiveone or more inputs comprising the components of the complex impedance,contact force, temperature, and potentially other variables, such as,for example, pressure. The ECU 32 can then process these inputs andgenerate an index to allow for the assessment of lesion formation as thelesion is being formed or after formation. Additionally, additionalfrequencies may be employed to better discriminate lesion changes intissue from temperature and contact force. Further, the generated indexmay be calculated based on discrete values for each input, on therespective changes in the input values, or a combination of both. Aswill be described in greater detail below, once calculated, the indexmay be evaluated in a similar manner as that described above withrespect to ECI calculations to assess lesion formation. Accordingly, insuch an embodiment, variables such as, for example and withoutlimitation, contact force and temperature are taken into account in theindex calculation itself as opposed to correcting or scaling apreviously calculated index as a result of the impact variables may haveon the index calculation.

In an exemplary embodiment, the ALI may be calculated using equation(7), which represents the equation in its most general form withoutaccounting for trabeculation:

ALI=a ₁ECI+a ₂ T+a ₃ F   (7)

In this equation the terms ECI, T, and F represent calculated ormeasured values of each of the ECI, temperature (T), and contact force(F) at a particular position or location of the tissue at a particulartime. The ECI is calculated as described in great detail above, whilethe temperature and contact force are measured using sensors mounted toor otherwise associated with the catheter 14. The coefficients a₁, a₂,and a₃ are predetermined values that are intended to account for thedependent relationship between each of the respective variables and theother measurements/calculations. These coefficients can be determined ina number of ways such as, for example, controlled experimentation orlinear regression analysis. In the first instance, one of thetemperature and force variables is fixed and the other is adjusted. Theeffect the adjustment has on the ECI is evaluated and a constant ofproportionality (i.e., coefficient) is determined. This process is thenrepeated for each variable until all of the coefficients have beendetermined. In the second instance, all of the experimental data isinput into a linear regression analysis and the “best fit” approach isused to figure out each coefficient. In either instance, once thecoefficients are determined, they are stored or programmed into the ECU32 or a memory/storage device associated therewith. It should be notedthat the coefficients are determined and programmed as part of themanufacturing or setup process of the system 10, and thus, are notdetermined during use of the system 10.

In another exemplary embodiment, ALI may be calculated using equation(8), which takes into account the confounding variable of trabeculation:

ALI(t)=a ₀ +a ₁ECI(t)+a ₂ T(t)+a ₃ F(t)+a ₄trab(t)=a ₀ ′+a ₁ECI(t)+a ₂T(t)+a ₃ F(t)   (8)

As briefly described above, the nature of trabeculation is such that itdoes not lend itself to direct measurement. However, the effect oftrabeculation can be accounted for using other variables, namely, forceand temperature. This is represented by the a₀′ term in equation (8). Inan exemplary embodiment, a₀′ is calculated using equation (9):

a ₀ ′=a ₀ +a ₄trab=−(a ₁ECI₀ +a ₂ T ₀ +a ₃F₀)   (9)

In equation (9), a₀′ is calculated at time t=0, which is preablation. Assuch, each term is measured/calculated prior to the performance of anablation procedure. The coefficients are determined as described above.The term a₀′ serves the function of an offset constant for subsequentALI calculations assuming the degree of trabeculation remains constant.

As can be seen in equation (8), the ALI is calculated as a function oftime. Accordingly, while the offset constant a₀′ is calculated at timet=0, the remaining terms in equation (8) are determined at time t=n,where n is a time either during or post-ablation that is later in timethan t=0. Therefore, in practice, a₀′ is calculated prior to an ablationprocedure. In an exemplary embodiment, the ALI is monitored insubstantially real-time as the ablation procedure progresses.Accordingly, a₀′ is processed with the values of the other terms ofequation (8) that are calculated at t=1, for example. As the procedurecontinues, a₀′ may be processed with the other terms that are calculatedat t=2, and so on. In another exemplary embodiment, the ALI is monitoredafter the completion of the ablation procedure (i.e., not necessarily inreal-time). Accordingly, if the ablation procedure ends at t=3, forexample, a₀′ is processed with the other terms that are calculated att=3. Thus, ALI may be monitored from just after the commencement of anablation procedure until after the ablation procedure ends in order toevaluate and assess the formation of the lesion. Alternatively, ratherthan keeping a₀′ constant throughout the ablation procedure, in anotherexemplary embodiment, a₀′ may be reevaluated before each individuallesion is formed during the ablation procedure. By reevaluating a₀′ inthis manner, each lesion site's trabeculation may be compensated forprior to the formation of the respective lesion.

Whether the ALI is calculated using equations (7) or (8), or any otherequation, the calculated ALI may be used in a number of ways to assess(i) whether the tissue has been changed (e.g., ablated), and/or (ii) thequality or extent of the lesion resulting from the ablation. In oneexemplary embodiment illustrated in FIG. 21, a first step 208 comprisesprogramming the ECU 32 with a predetermined minimum ALI threshold thatrepresents the minimum ALI level for which contact between the electrode12 and unchanged/insufficiently changed (e.g., unablated or not fullyablated) tissue is attained. In an exemplary embodiment, this thresholdvalue is zero, as anything above zero is indicative of at least somedegree or extent of ablation. The ECU 32 may be preprogrammed with thethreshold or a user may input the threshold via a conventional I/Ointerface, thereby allowing the threshold to be changed. To evaluate theformation of a lesion line or ablated area, in a second step 210, whilemaintaining contact with the tissue, the electrode 12 is moved along orabout the area of tissue that was subjected to an ablation procedure. Ina third step 212, as the electrode 12 is moved, one or more ALIcalculations are made at various points in time. For each calculatedALI, a fourth step 214 is performed that comprises comparing thecalculated ALI with the predetermined threshold. If the calculated ALIexceeds the threshold, a determination can be made that the tissue atthat particular location was changed (e.g., ablated). Otherwise, adetermination can be made that the tissue was unchanged or notsufficiently changed (e.g., not ablated or not fully ablated).

In a fifth step 216 an indication is provided to the clinician/physicianas to what type of tissue with which the electrode 12 is in contact.Accordingly, the ECU 32 is configured to generate a signalrepresentative of an indicator corresponding to the type of tissue(e.g., changed (e.g., ablated) or unchanged/insufficiently changed(e.g., unablated or not fully ablated), for example) that the electrode12 is in contact with based on the ALI calculation and comparison. Asdescribed in great detail above with respect to the use of ECI in lesionassessment, the indicator may take many forms. The description relatingto the various forms of indicators set forth above applies here withequal force, and therefore, will not be repeated.

In an exemplary embodiment, in a sixth step 218 a determination is madeas to whether the portion of the tissue at the particular location beingevaluated has been changed (e.g., ablated). The particular location ofthe portion of the tissue may be determined using the mapping,visualization, and navigation system 30. If the tissue has been changed(e.g., ablated), the calculated ALI and ablation information may bestored in a storage medium, such as, for example, memory 92/116. In aseventh step 220, the system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 210.

If, on the other hand, the tissue has not been changed (e.g., ablated),then the physician/clinician can determine whether it should be ablated.Alternatively, in a robotic application, a robotic controller, or othercomponent of the system, can make such a determination. If the tissueshould be ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 210. If, however, the tissueshould not be ablated, then the ALI and ablation information may bestored in a storage medium, such as, for example, memory 92/116. Thesystem 10 then determines whether the ablation procedure can be ended.If “yes,” then the ablation procedure is stopped. If “no,” then theprocess begins again at step 210.

While the aforementioned embodiment is directed towards determiningwhether tissue has been changed (e.g., ablated), in other exemplaryembodiments determinations can be made as to whether tissue has beenchanged as well as to the quality or extent of change (e.g., ablation)(i.e., the degree of change). One such example is illustrated in FIG.22. In a first step 222, an ALI range is defined that has a lowerthreshold corresponding to an ALI value indicative of the tissue beingunchanged/insufficiently changed (e.g., unablated or not fully ablated),and an upper threshold corresponding to an ALI value indicative of thetissue being changed (e.g., ablated). In an exemplary embodiment thelower threshold value equals zero and the upper threshold value equalsone (i.e., ALI range is 0-1). In such an embodiment, the goal forchanged (e.g., ablated) tissue would be to have an ALI value of between0 and the immediate neighborhood of 1, and to not go much above 1 asanything exceeding 1, in this particular embodiment, would be indicativeof over-ablation. These thresholds may be set by either preprogrammingthem into the ECU 32, or a user may input them using a conventional I/Ointerface. In a second step 224, a current ALI is calculatedcorresponding to the portion of the tissue in contact with the electrode12. In a third step 226, the calculated ALI is compared to the ALIrange. Based on this comparison, a determination can be made as to (i)whether the tissue has been changed (e.g., ablated), and (ii) if thetissue has been changed, the quality or extent of the change (e.g.,ablation).

More particularly, if the calculated ALI equals zero (or nearly zero),then it can be determined that the tissue at that particular locationhas not been changed, or at least not sufficiently changed (e.g., thetissue is unablated or not fully ablated). If, on the other hand, theALI is above zero, then it can be determined that the tissue has, infact, been changed (e.g., ablated). Further, based on the particularvalue of the calculated ALI, it can be determined whether the tissue hasbeen mildly changed or ablated (ALI closer to 0) or more substantiallychanged or ablated (ALI closer to 1). In one exemplary embodiment theECU 32 may be configured to look up the value of the ALI in a look-uptable, for example, stored in the ECU 32 or in another component of thesystem accessible by the ECU 32 that contains values of ALI andcorresponding indications of the extent or degree of the ablation. Thisindication may then be communicated to the physician/clinician orrobotic controller to assess whether the extent of the ablation orchange in the tissue is acceptable. While the extent/quality of theablation aspect of the invention is described with respect to thisparticular embodiment, it will be appreciated by those of ordinary skillin the art that it applies to any embodiment in which an ALI iscalculated.

In a fourth step 228, an indication is provided to theclinician/physician as to whether the tissue that is in contact with theelectrode 12 has been changed (e.g., ablated), and/or as to the degreeor quality of the change (e.g., ablation). Accordingly, based on the ALIcalculation and comparison, the ECU 32 is configured to generate asignal representative of an indicator corresponding to the type oftissue with which the electrode 12 is in contact. In an exemplaryembodiment, the indicator, or another indicator, may also indicate thequality or extent of the ablation. As described above in great detail,these indicators may take many forms. The description set forth aboverelating to the indicators applies here with equal force, and therefore,will not be repeated.

In an exemplary embodiment, in a fifth step 230 a determination is madeas to whether the portion of the tissue at the particular location beingevaluated has been changed (e.g., ablated). In an exemplary embodiment,this inquiry may further include whether the extent to which the tissuehas been changed is acceptable (i.e., meets quantitative standards). Theparticular location of the portion of the tissue may be determined usingthe mapping, visualization, and navigation system 30. If the tissue hasbeen changed (e.g., ablated) and/or if the change in the tissue isacceptable, the calculated ALI and ablation information may be stored ina storage medium, such as, for example, memory 92/116. In a sixth step232, the system 10 then determines whether the ablation procedure can beended. If “yes,” then the ablation procedure is stopped. If “no,” thenthe process begins again at step 222.

If, on the other hand, the tissue has not been changed, or at least notsufficiently changed (e.g., the tissue is unablated or not fullyablated), then the physician/clinician can determine whether it shouldbe ablated or re-ablated. Alternatively, in a robotic application, arobotic controller, or other component of the system, can make such adetermination. If the tissue should be ablated or re-ablated, ablativeenergy can be applied to the tissue at that particular location.Accordingly, the physician/clinician may move the catheter 14 to theparticular location requiring ablation and then cause ablative energy tobe applied. Alternatively, in a robotic application, the roboticcontroller may cause the catheter 14 to move to the particular locationrequiring ablation and then cause ablative energy to be applied. In suchan embodiment, the system 30 may be used by the robotic controller todetermine where the catheter is and where it needs to go, as well as toassist with the direction of the movement of the catheter to the desiredlocation. Once the tissue is ablated, the process may then proceedstarting at step 222. If, however, the tissue should not be ablated orre-ablated, then the ALI and ablation information may be stored in astorage medium, such as, for example, memory 92/116. The system 10 thendetermines whether the ablation procedure can be ended. If “yes,” thenthe ablation procedure is stopped. If “no,” then the process beginsagain at step 222.

In another exemplary embodiment, rather than comparing a calculated ALIwith an ALI threshold or ALI range, the change in ALI over either timeor space (i.e., distance) is evaluated. In an exemplary embodiment, thechange in ALI over a predetermined amount of time

$\left( {{i.e.},\frac{{ALI}}{t}} \right)$

is determined and evaluated. FIG. 23 illustrates an exemplary embodimentof a methodology based on change in ALI over time.

In a first step 234, an ALI calculation for a particular area of thetissue 16 is made and then stored in a storage medium, such as, forexample, memory 92/116. In an exemplary embodiment this may correspondto the ALI at time t=1. In a second step 236, the ECU 32 calculatesanother ALI after a predetermined period of time has elapsed (i.e., timet=2). This calculated ALI may correspond to the same area of the tissue16 or a different area of the tissue 16. The ECU 32 may be preprogrammedwith the time interval or sampling rate that constitutes thepredetermined period of time, or it may be entered by the user via aconvention I/O interface.

In a third step 238, the ECU 32 compares the previously stored ALIcalculation (ALI at t=1) with the current ALI calculation (ALI at t=2)and determines if there is a change, and if so, the degree of suchchange. No change in the ALI is indicative of the electrode remaining incontact with either changed or unchanged/insufficiently changed tissue(i.e., the electrode has not moved from unchanged or insufficientlychanged (e.g., unablated or not fully ablated) tissue to changed (e.g.,ablated) tissue, or vice versa, and therefore, there is no appreciablechange in the ALI) or that the particular extent to which the tissue hasbeen changed has not itself changed. A “positive” change value isindicative of the electrode 12 moving from contact with changed (e.g.,ablated) tissue to unchanged/insufficiently changed (e.g., unablated ornot fully ablated) tissue, or from tissue having a higher extent ofchange to tissue of lower extent of change (i.e., higher ALI for changed(e.g., ablated) or more changed tissue compared to lower ALI forunchanged or insufficiently changed (e.g., unablated or not fullyablated) or less changed tissue results in a positive number). Finally,a “negative” change value is indicative of the electrode 12 moving fromcontact with unchanged or insufficient changed (e.g., unablated or notfully ablated) tissue to changed (e.g., ablated) tissue or from tissuehaving a lower extent of change to tissue of a higher extent of change(i.e., lower ALI for unchanged or insufficiently changed (e.g.,unablated or not fully ablated) or less changed tissue compared tohigher ALI for changed (e.g., ablated) or more changed tissue results ina negative number).

In an instance where the comparison of the ALI calculations results in achange—whether positive or negative—in an exemplary embodiment, thedegree of change may be taken into account such that the change mustmeet a predetermined threshold to be considered a change in contact fromchanged (e.g., ablated) to unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue (or vice versa). This allows forsome change in ALI without necessarily indicating a change in thetissue.

With continued reference to FIG. 23, in a fourth step 240, an indicationis provided to the clinician/physician, or to a robotic controller in arobotics-based system, as to whether the portion of the tissue that ispresently in contact with the electrode 12 is changed (e.g., ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue and/or to what extent the tissue has been changed. Accordingly,based on the comparison of ALI calculations, the ECU 32 is configured togenerate signal representative of an indicator corresponding to the typeof tissue with which the electrode 12 is in contact. In an exemplaryembodiment, the indicator, or another indicator, may also indicate thequality or extent of the change (e.g., ablation). As described above ingreat detail, these indicators may take many forms. The description setforth above relating to these indicators applies here with equal force,and therefore, will not be repeated. This process repeats itself as theelectrode 12 continues to move. Accordingly, each ALI calculation issaved in the memory 92/116 so that it may be compared to one or moresubsequent ALI calculations.

With continued reference to FIG. 23, in an exemplary embodiment, in afifth step 242 a determination is made as to whether the portion of thetissue at the particular location being evaluated has been changed(e.g., ablated). In another exemplary embodiment this inquiry mayfurther include whether the extent to which the tissue has been changedis acceptable (i.e., meets certain standards). The particular locationof the portion of the tissue may be determined using the mapping,visualization, and navigation system 30. If the tissue has been changed,and/or if the change is acceptable, the calculated ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. In a sixth step 244, the system 10 then determineswhether the ablation procedure can be ended. If “yes,” then the ablationprocedure is stopped. If “no,” then the process begins again at step234.

If, on the other hand, the tissue has not been changed, or at least notsufficiently or acceptably changed (e.g., the tissue is unablated or notfully ablated), then the physician/clinician can determine whether itshould be ablated or re-ablated. Alternatively, in a roboticapplication, a robotic controller, or other component of the system, canmake such a determination. If the tissue should be ablated orre-ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 234. If, however, the tissueshould not be ablated or re-ablated, then the ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. The system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 234.

In another exemplary embodiment, besides comparing a calculated ALI withan ALI threshold or evaluating the change in the ALI over apredetermined time interval, the change in the ALI over a predeterminedspace or surface distance

$\left( {{i.e.},\frac{{ALI}}{s}} \right)$

is determined and evaluated. FIG. 24 illustrates an exemplary embodimentof a methodology based on change in ALI over distance or space. Itshould be noted that this particular embodiment finds particularapplication in the instance wherein trabeculation is not a confoundingvariable or concern (i.e., the tissue being evaluated is smooth and freeof trabeculae).

In a first step 246, an ALI calculation is made for a particular area ofthe tissue 16 and then stored in a storage medium, such as, for example,memory 92/116. In a second step 248, the ECU 32 calculates another ALIcalculation after it is determined that the electrode 12 has traveled apredetermined distance either longitudinally along the longitudinal axisof a lesion, or laterally relative to the longitudinal axis to anotherarea of the tissue 16. In an exemplary embodiment, the ECU 32 isconfigured to receive location data (such as x, y, z coordinates) fromthe mapping, visualization, and navigation system 30 and to calculatechange in distance relative to prior stored location data also receivedfrom system 30. In another exemplary embodiment, system 30 is configuredto process the location data to calculate a change in distance and toprovide the change to the ECU 32 for it determine whether thepredetermined sampling distance has been met. Accordingly, thecalculation may be triggered when the electrode moves a certaindistance. The predetermined distance may be programmed into the ECU 32or may be entered by a user via a conventional I/O interface.

In a third step 250, the ECU 32 compares the previously stored ALIcalculation with the current ALI calculation and determines if there isa change, and if so, the degree of such change. No change in the ALI isindicative of the electrode remaining in contact with the same type oftissue (i.e., the electrode has not moved from unchanged/insufficientlychanged (e.g., unablated or not fully ablated) to changed (e.g.,ablated) tissue, or vice versa, and therefore, there is no appreciablechange in the ALI) or that the particular degree or extent to which thetissue has been changed has itself not changed. A “positive” changevalue is indicative of the electrode 12 moving from contact with changed(e.g., ablated) tissue to unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue or from tissue having a higherextent of change to tissue of lower extent of change (i.e., higher ALIfor changed (e.g., ablated) or more changed tissue compared to lower ALIfor unchanged or not sufficiently changed (e.g., unablated or not fullyablated) or less changed tissue results in a positive number). Finally,a “negative” change value is indicative of the electrode 12 moving fromcontact with unchanged or insufficiently changed (e.g., unablated or notfully ablated) tissue to changed (e.g., ablated) tissue, or from tissuehaving a lower extent of change to tissue of a higher extent of change(i.e., lower ALI for unchanged or not sufficiently changed (e.g.,unablated or not fully ablated) or less changed tissue compared tohigher ALI for changed (e.g., ablated) or more changed tissue results ina negative number).

In an instance where the comparison of the ALI calculations results in achange—whether positive or negative—in an exemplary embodiment, thedegree of change may be taken into account such that the change mustmeet a predetermined threshold to be considered a change in contact fromchanged (e.g., ablated) to unchanged or insufficiently changed (e.g.,unablated or not fully ablated) tissue (or vice versa). This allows forsome change in ALI without necessarily indicating a change in thetissue.

With continued reference to FIG. 24, in a fourth step 252, an indicationis provided to the clinician/physician, or to a robotic controller in arobotics-based system, as to whether the portion of the tissue that ispresently in contact with the electrode 12 is changed (e.g., ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue and/or to what extent the tissue has been changed (e.g.,ablated). Accordingly, based on the comparison of ALI calculations, theECU 32 is configured to generate signal representative of an indicatorcorresponding to the type of tissue with which the electrode 12 is incontact. In an exemplary embodiment, the indicator, or anotherindicator, may also indicate the quality or extent of the change (e.g.,ablation). As described above in great detail, these indicators may takemany forms. The description set forth above relating to these indicatorsapplies here with equal force, and therefore, will not be repeated. Thisprocess repeats itself as the electrode 12 continues to move.Accordingly, each ALI calculation is saved in the memory 92/116 so thatit may be compared to one or more subsequent ALI calculations.

With continued reference to FIG. 24, in an exemplary embodiment, in afifth step 254 a determination is made as to whether the portion of thetissue at the particular location being evaluated has been changed(e.g., ablated). In another exemplary embodiment this inquiry mayfurther include whether the extent to which the tissue has been changedis acceptable (i.e., meets certain standards). The particular locationof the portion of the tissue may be determined using the mapping,visualization, and navigation system 30. If the tissue has been changedand/or if the change is acceptable, the calculated ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. In a sixth step 256, the system 10 then determineswhether the ablation procedure can be ended. If “yes,” then the ablationprocedure is stopped. If “no,” then the process begins again at step246.

If, on the other hand, the tissue has not been changed, or at least notsufficiently or acceptably changed (e.g., the tissue is unablated or notfully ablated), then the physician/clinician can determine whether itshould be ablated or re-ablated. Alternatively, in a roboticapplication, a robotic controller, or other component of the system, canmake such a determination. If the tissue should be ablated orre-ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 246. If, however, the tissueshould not be ablated or re-ablated, then the ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. The system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 246.

In another exemplary embodiment, two or more ALI calculations for tissueat a particular location at two different points in time can beevaluated to determine whether the tissue at that particular locationhas been changed (e.g., ablated), and/or to what extent the tissue hasbeen changed. More specifically, and with reference to FIG. 25, in afirst step 258 an ALI calculation is made for tissue at a particularlocation. In a second step 260, the ALI calculation and thecorresponding location—which may be acquired from the mapping,visualization and navigation system 30—are saved in a storage medium,such as, for example and without limitation, the memory 92/116.

As the electrode 12 moves, a number of ALI calculations can be made.Once the procedure has been completed, in a third step 262, theelectrode 12 can be brought back over the area that was to be ablated todetermine if tissue at a particular location was, in fact, changed,and/or to what extent. In a fourth step 264, as the electrode visitseach location for which a prior ALI calculation was made, another ALIcalculation is made. In a fifth step 266, the ECU 32 accesses the priorALI calculation that corresponds to the particular location, andcompares the ALI calculations corresponding to the particular locationto determine whether the ALI has changed. As described in greater detailabove, whether the ALI value, or the change therein, meets, exceeds, orfalls below a predetermined threshold or ALI range, the ECU 32 is ableto determine whether the tissue at that particular location has beenchanged (e.g., ablated), and/or to what extent. This process thencontinues as the electrode 12 continues to move along or about aperceived lesion line or area, or as long as the clinician/physiciandesires.

In an exemplary embodiment, in a sixth step 268, the ECU 32 may beconfigured to provide an indication of the respective ALI values, whicha user may take into consideration and make a determination as towhether the tissue is changed (e.g., ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated),and/or to what extent the tissue was changed. In either instance, thedescription set forth in great detail above relating to the generationand/or provision of indicators applies here with equal force, andtherefore, will not be repeated. Additionally, the description set forthabove relating to the tolerances and/or the substantiality of the changein ALI applies here with equal force, and therefore, likewise will notbe repeated here.

In an exemplary embodiment, in a seventh step 270 a determination ismade as to whether the portion of the tissue at the particular locationbeing evaluated has been changed (e.g., ablated). In another exemplaryembodiment this inquiry may further include whether the extent to whichthe tissue has been changed is acceptable (i.e., meets certain standardssuch that the tissue has been changed). The particular location of theportion of the tissue may be determined using the mapping,visualization, and navigation system 30. If the tissue has been changedand/or if the change is acceptable, the calculated ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. In an eighth step 272, the system 10 then determineswhether the ablation procedure can be ended. If “yes,” then the ablationprocedure is stopped. If “no,” then the process begins again at step258.

If, on the other hand, the tissue has not been changed, or at least notsufficiently or acceptably changed (e.g., the tissue is unablated or notfully ablated), then the physician/clinician can determine whether itshould be ablated or re-ablated. Alternatively, in a roboticapplication, a robotic controller, or other component of the system, canmake such a determination. If the tissue should be ablated orre-ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 258. If, however, the tissueshould not be ablated or re-ablated, then the ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. The system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 258.

In another exemplary embodiment, rather than evaluating the finite orraw ALI calculation or determining a change in two ALI calculations, therate of change of the ALI or the slope of a line between at least twoALI calculations over a predetermined amount of time

$\left( {{i.e.},\frac{^{2}{ALI}}{t^{2}}} \right)$

is determined and used to assess lesion formation. More particularly,when the electrode 12 changes from one type of tissue (e.g., changedtissue) to another type of tissue (e.g., unchanged/insufficientlychanged tissue), or from tissue that is more changed to tissue that isless changed, the rate of change or the change in the slope over apredetermined amount of time is most evident. In other words, if theelectrode 12 remains in contact with either changed (e.g., ablated)tissue or unchanged or insufficiently changed (e.g., unablated or notfully ablated) tissue, respectively, the rate of change in the ALI maynot be appreciable. However, when the electrode 12 moves from changed tounchanged or insufficiently changed tissue (or from tissue that is morechanged to tissue that is less changed), or vice versa, the rate ofchange in the ALI may be appreciable. Thus, if the rate of change over apredetermined period of time meets, exceeds, or falls below (dependingon the circumstances) a predetermined threshold value, then one is ableto determine what type of tissue with which the electrode 12 iscurrently in contact and/or the extent to which that tissue was changed(e.g., ablated). Accordingly, the rate of change in ALI or the change inthe slope over a predetermined period of time can be useful in assessinglesion formation.

FIG. 26 illustrates one exemplary embodiment of a methodology that usesthe rate of change of the ALI. In this embodiment, the memory 92/116stores a predetermined number of previously calculated ALI calculations.As described above, the memory 92/116 may be part of the ECU 32 or maybe a separate and distinct component that is accessible by the ECU 32such that the ECU 32 may retrieve the stored ALIS. In an exemplaryembodiment, the ECU 32 is configured to access the memory 92/116 and tocalculate the rate of change in the ALI or the slope of a line drawnbetween a current or most recent ALI calculation and one or morepreviously calculated ALIS. Depending on if the rate of change meets,exceeds, or falls below a predetermined threshold that is programmedinto ECU 32, the ECU 32 may be configured to recognize that theelectrode 12 is in contact with changed (e. g. , ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue (or tissue that is more or less changed), or may simply providethe rate of change to a user for the user to determine the type oftissue with which the electrode is in contact or the extent to which thetissue is changed (e.g., ablated).

Accordingly, with continued reference to FIG. 26, in a first step 274 acurrent ALI is calculated and may be stored in the memory 92/116. In asecond step 276, the ECU 32 accesses the memory 92/116 to retrieve oneor more previously calculated ALIs. In a third step 278, the rate ofchange or slope between the current ALI and the one or more previouslycalculated ALIs stored in the memory 92/116 is calculated. In a fourthstep 280, the ECU 32 determines whether the electrode 12 is in contactwith changed (e.g., ablated) or unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue (or the extent to which thetissue was changed) based on the calculated rate of change. In anexemplary embodiment, in a fifth step 282, an indication may be providedto the clinician/physician as to whether the tissue that is presently incontact with the electrode 12 is changed (e.g., ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue, or to determine to what extent that tissue has been changed(e.g., ablated). Accordingly, the ECU 32 may be further configured togenerate a signal representative of an indicator corresponding to thetype of tissue with which the electrode 12 is in contact. In anexemplary embodiment, this indicator or another indicator may alsoindicate the extent or quality of the ablation or the change in thetissue. The description set forth in great detail above relating to thegeneration and/or provision of such indicators applies here with equalforce, and therefore, will not be repeated.

In an exemplary embodiment, in a sixth step 286 a determination is madeas to whether the portion of the tissue at the particular location beingevaluated has been changed (e.g., ablated). In another exemplaryembodiment this inquiry may further include whether the extent to whichthe tissue has been changed is acceptable (i.e., meets certain standardssuch that the tissue has been changed). The particular location of theportion of the tissue may be determined using the mapping,visualization, and navigation system 30. If the tissue has been changedor ablated and the change (e.g., ablation) is acceptable, the calculatedALI and ablation information may be stored in a storage medium, such as,for example, memory 92/116. In a seventh step 288, the system 10 thendetermines whether the ablation procedure can be ended. If “yes,” thenthe ablation procedure is stopped. If “no,” then the process beginsagain at step 274.

If, on the other hand, the tissue has not been changed, or at least notsufficiently or acceptably changed (e.g., the tissue is unablated or notfully ablated), then the physician/clinician can determine whether itshould be ablated or re-ablated. Alternatively, in a roboticapplication, a robotic controller, or other component of the system, canmake such a determination. If the tissue should be ablated orre-ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 274. If, however, the tissueshould not be ablated or re-ablated, then the ALI and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. The system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 274.

In another exemplary embodiment, rather than evaluating finite or rawALI calculations or the rate of change in such calculations, ALI may beused, in part, to calculate an ALI rate (ALIR). The ALIR can be used inlesion assessment. In an exemplary embodiment, the ECU 32 is configuredto calculate the ALIR, however, the present invention is not meant to beso limited. Rather, other processors or components may be employed toperform the calculation.

In simple terms, the ALIR is calculated by dividing the change in ALIover a predetermined amount of time by the change in the distance orposition of the electrode 12 over the same predetermined amount of time.The change in the ALI is calculated by sampling the ALI calculationsperformed by the ECU 32 at a predetermined rate and then determining thedifference between a current calculation and the most recent previouscalculation, for example, that may be stored in the memory 92/116. Inanother exemplary embodiment, the difference may be between a currentcalculation and multiple previous calculations, or an average ofprevious calculations.

In an exemplary embodiment, the ECU 32 samples the calculated ALI at apredetermined sampling rate, and then calculates the change in the ALIover that time interval. It will be appreciated by those of ordinaryskill in the art that the ALI may be sampled at any number of timeintervals or rates. For example, in one embodiment using knowntechniques, the sampling is timed or synchronized to coincide with thecardiac cycle of the patient's heart so as to always sample at the samepoint in the cardiac cycle. In another embodiment, the sampling of theALI is dependent upon a triggering event rather than a defined timeinterval. For instance, the sampling of the ALI may be dependent uponthe change in the distance/position of the electrode 12 meeting apredetermined threshold. More specifically, when it is determined thatthe electrode 12 has moved a predetermined distance, the ECU 32 willsample the ALI over the time interval it took the electrode 12 to movethe predetermined distance. Accordingly, it will be appreciated by thoseof ordinary skill in the art that many different sampling rates and/ortechniques may be used to determine the change in ALI.

With respect to the change in distance/location of the electrode, asdescribed above this change may be calculated by the ECU 32 based onlocation coordinates provided to it by the system 30, or may becalculated by the system 30 and then provided to the ECU 32. As with thechange in ALI, the change in distance or location is determined bysampling the location coordinates of the electrode 12 at a predeterminedsampling rate. From this, the change in distance over time can bederived. As with the sampling of the ALI calculations, the locationcoordinates of the electrode 12 are sampled at a predetermined samplingrate and then the change in the location is calculated over that timeinterval. It will be appreciated by those of ordinary skill in the artthat the location/position may be sampled at various rates and usingvarious techniques (e.g., synchronization with cardiac cycle).Accordingly, the present invention is not limited one particularsampling rate/technique. It should be noted that this particularembodiment finds particular application in the instance whereintrabeculation is not a confounding variable or concern (i.e., the tissuebeing evaluated is smooth and free of trabeculae.

Once the two “change” calculations have been made, the ECU 32 is able tocalculate the ALIR by dividing the change in the ALI by the change inthe distance or location of the electrode 12. In an exemplaryembodiment, the calculated ALIR is stored in a storage medium, such as,for example, memory 92/116, that is accessible by the ECU 32.

Once the ALIR has been calculated, it may be used to assess, among otherthings, what type of tissue the electrode 12 is in contact with (e.g.,changed (e.g., ablated) versus unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue), and/or to what extent thetissue has been changed. In an exemplary embodiment illustrated in FIG.27, the ALIR is calculated in a first step 288 by dividing the change inALI by the change in distance. In a second step 290, the calculated ALIRis evaluated to determine whether the calculated ALIR meets, exceeds, orfalls below a predefined threshold value. Depending on where thecalculated ALIR falls with respect to the threshold, a determination canbe made as to what type of tissue the electrode 12 is in contact with,and/or to what extent the tissue has been changed.

More particularly, in a first substep 292 of step 290, an ALIR thresholdis defined. This threshold may be set by either preprogramming it intothe ECU 32, or a user may manually input it into the ECU 32 using aconventional I/O interface.

In a second substep 294 of second step 290, the calculated ALIR iscompared to the predefined threshold. Based on this comparison, thedetermination is made as to what type of tissue the electrode 12 iscontacting (e.g., changed (e.g., ablated) or unchanged/insufficientlychanged (e.g., unablated or not fully ablated)) or from what type oftissue from which the electrode has traveled. To what extent the tissuehas been changed may also be determined. In an exemplary embodiment, ina third step 296, the ECU 32 may be configured to provide an indicationas to the value of the ALIR, which a user may take into considerationand make a determination as to whether the tissue is changed (e.g.,ablated) or unchanged/insufficiently changed (e.g., unablated or notfully ablated), and/or to what extent the tissue has been changed. Thedescription set forth in great detail above relating to the generationand/or provision of indicators applies here with equal force, andtherefore, will not be repeated.

In an exemplary embodiment, in a fourth step 298 a determination is madeas to whether the portion of the tissue at the particular location beingevaluated has been changed (e.g., ablated). In another exemplaryembodiment this inquiry may further include whether the extent to whichthe tissue has been changed is acceptable (i.e., meets certain standardssuch that the tissue has been changed). The particular location of theportion of the tissue may be determined using the mapping,visualization, and navigation system 30. If the tissue has been changed(e.g., ablated) and the change (e.g., ablation) is acceptable, thecalculated ALI/ALIR and ablation information may be stored in a storagemedium, such as, for example, memory 92/116. In a fifth step 300, thesystem 10 then determines whether the ablation procedure can be ended.If “yes,” then the ablation procedure is stopped. If “no,” then theprocess begins again at step 288.

If, on the other hand, the tissue has not been changed, or at least notsufficiently or acceptably changed (e.g., the tissue is unablated or notfully ablated), then the physician/clinician can determine whether itshould be ablated or re-ablated. Alternatively, in a roboticapplication, a robotic controller, or other component of the system, canmake such a determination. If the tissue should be ablated orre-ablated, ablative energy can be applied to the tissue at thatparticular location. Accordingly, the physician/clinician may move thecatheter 14 to the particular location requiring ablation and then causeablative energy to be applied. Alternatively, in a robotic application,the robotic controller may cause the catheter 14 to move to theparticular location requiring ablation and then cause ablative energy tobe applied. In such an embodiment, the system 30 may be used by therobotic controller to determine where the catheter is and where it needsto go, as well as to assist with the direction of the movement of thecatheter to the desired location. Once the tissue is ablated, theprocess may then proceed starting at step 288. If, however, the tissueshould not be ablated or re-ablated, then the ALFALIR and ablationinformation may be stored in a storage medium, such as, for example,memory 92/116. The system 10 then determines whether the ablationprocedure can be ended. If “yes,” then the ablation procedure isstopped. If “no,” then the process begins again at step 288.

It should be noted that while the ALI described in great detail above iscalculated as a function of time and takes into account confoundingvariables of temperature, contact force, and trabeculation, in otherexemplary embodiments indices are calculated that take into accountadditional or fewer variables. These indices remain within the spiritand scope of the present invention. For example, in another exemplaryembodiment, the ECU 32 may be configured to receive one or more inputsof the components of the complex impedance and contact force, forexample, and to then generate an index to allow for the assessment oflesion formation. The generated index may be calculated based ondiscrete values for each input, on the respective changes in the inputvalues, or a combination of both. Once calculated, the index may beevaluated in a similar manner as that described above with respect toECI and ALI calculations to assess lesion formation. Accordingly, insuch an embodiment, contact force is taken into account in the indexcalculation as opposed to correcting or scaling a calculated index(e.g., ECI) as a result of the impact contact force may have on theindex calculation.

Accordingly, indices taking into account different variables may becalculated that reduce the influence these variables have on thecalculated index. As a result, one or more indices can be calculatedthat are substantially insensitive to variables such as temperature andcontact force, and responsive virtually solely on tissue changes causedby ablation to determine simply whether the tissue has been changed orablated and/or to what extent the tissue has been changed (e.g.,ablated).

While the description with respect to lesion assessment has beengenerally focused on the use of ECI, or other derivatives thereof,lesion assessment can be carried out using other methodologies ortechniques. For example, in an exemplary embodiment, the compleximpedance, and/or the components thereof, may be used to assess tissuetemperature and/or lesion formation.

In one exemplary embodiment, the change in the phase angle of theimpedance can be evaluated to determine what type of tissue theelectrode 12 is in contact with. More particularly, a constant voltagesource, or more preferably, a constant current source, is used and theshift in the phase angle (i.e., change in the phase angle) is measured.When the electrode 12 is in contact with a lesion or tissue that hasbeen changed (e.g., ablated), the phase angle change decreases. When theelectrode 12 moves from contact with changed (e.g., ablated) tounchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue, the phase angle change increases. Accordingly, by assessing orevaluating the change in the phase angle, a determination can be made asto what type of tissue with which the electrode is in contact.

In another exemplary embodiment, the complex impedance itself can beused to assess lesion formation. One challenge with the use of compleximpedance is that the change in the impedance caused by temperature—asopposed to change in the tissue (i.e., ablation of tissue)—must be takeninto account and separated from the calculation. One difference betweenthe two is that when a change in the impedance is induced by a change inthe temperature, the impedance may appreciably recover once the tissuehas cooled. However, if the change is induced due to actual change inthe tissue (i.e., the tissue has been changed (e.g., ablated)), thechange in the impedance is residual and does not recover topredetermined levels/values. Accordingly, once the two changes inimpedance are separated such that the change due to ablation isisolated, one can assess the lesion formation based on the magnitude ofthe change in the impedance, and therefore, determine whether the tissueat a particular location has been changed (e.g., ablated) orunchanged/insufficiently changed (e.g., unablated or not fully ablated).

Likewise, one could use the temperature induced change in compleximpedance to calculate temperature changes. For example, if theelectrode 12 is held in a constant position (or returned to a positionpreviously measured), the electrode 12 may observe an impedance changeover time, e.g., the phase angle, that corresponds to a drop in tissuetemperature after ablation. As the tissue cools and returns to ambienttemperatures, the change in the phase angle will level off. Particularlyin use with an irrigated catheter, where tissue temperature changes maybe difficult to measure, the changes in the impedance may allow theclinician to determine the tissue temperature and, as a result,determine when it is either safe or dangerous to resume ablation withoutover heating the tissue.

One additional variable to account for in this technique or methodologyis the contact force applied to the electrode 12 against the tissue. Thecontact force may change with tissue temperature, which can have animpact on the impedance measurements. Accordingly, the contact force canbe measured as described above and taken into account to determine andisolate the change in impedance induced solely by the change in thetissue properties or attributes.

Whether the complex impedance or constituent components thereof are usedto assess lesion formation, an indication of themeasurements/calculations and/or determinations as to whether tissue ata particular location has been changed (e.g., ablated) may becommunicated or displayed in the same manner described above.Accordingly, such discussion will not be repeated here.

Whether ECI, a derivative thereof, ALI or other similar index, compleximpedance, or the constituent components of the impedance are used forlesion assessment, in an exemplary embodiment the ECU 32 is programmedwith a computer program (i.e., software) encoded on a computer storagemedium for assessing whether tissue at a particular location has beenchanged (e.g., ablated). Accordingly, the program includes code forcarrying out one or more of the various techniques/methodologiesdescribed above.

The computer program may be a part of a system provided for identifyingthe location of a device or for visualization, mapping, and navigationof internal body structures, such as, for example, system 30. Asdescribed above, such systems include the EnSite NavX™ Systemcommercially available from St. Jude Medical, Inc. and as generallyshown with reference to commonly assigned U.S. Pat. No. 7,263,397entitled “Method and Apparatus for Catheter Navigation and Location andMapping in the Heart,” the disclosure of which is hereby incorporatedherein by reference in its entirety. Alternative systems includeBiosense Webster Carto™ System, commonly available fluoroscopy systemsor a magnetic location system such as the gMPS system from MediguideLtd., and as generally shown with reference to U.S. Pat. No., 7,386,339entitled “Medical Imaging and Navigation System”, the disclosure ofwhich is incorporated herein by reference in its entirety.

In use, it can be advantageous to create a map in real time. This stepis conducted differently in each of the systems known in the art. Forillustration purposes only, it will be described in the context of theEnSite System, but may be readily adapted for use in other systems.Briefly, FIG. 28 shows a system level diagram in schematic form. Thepatient 208 is depicted as an oval for clarity. Three sets of surfaceelectrodes are shown as 210, 212 along a Y-axis; as 214, 216 along anX-axis; and 218, 220 along a Z-axis. Patch electrode 218 is shown on thesurface closest the observer and patch 220 is shown in outline form toshow the placement on the back of patient 208. An additional patchelectrode called a “belly” patch is also seen in the figure as patchelectrode 222. Each patch electrode is independently connected to amultiplex switch 224. The subject tissue 226 lies between these varioussets of patch electrodes. Also seen in this figure is a representativecatheter 228 having a single distal electrode 230 for clarity. A fixedreference electrode 232 attached to a heart wall is also seen in thefigure on an independent catheter 234.

Each patch electrode is coupled to the switch 224 and pairs ofelectrodes are selected by software running on computer 236, whichcouples the patches to the signal generator 238. A pair of electrodes,for example 210, 212, are excited by the signal generator 238 and theygenerate a field in the body of the patient 208 and the heart 226.During the delivery of the current pulse the remaining patch electrodesare referenced to the belly patch 208 and the voltages impressed onthese remaining electrodes are measured by the A to D converter 240.Suitable low pass filtering of the digital data is subsequentlyperformed in software to remove electronic noise and cardiac motionartifact after suitable low pass filtering in filter 242. In thisfashion, the surface patch electrodes are divided into driven andnon-driven electrode sets. While a pair of electrodes is driven by thecurrent generator 238, the remaining non-driven electrodes are used asreferences to synthesize the orthogonal drive axes.

All of the raw patch voltage data is measured by the A to D converter240 and stored in the computer under the direction of software. Thiselectrode excitation process occurs rapidly and sequentially asalternate sets of patch electrodes are selected and the remainingmembers of the set are used to measure voltages. This collection ofvoltage measurements is referred to herein as the “patch data set.” Thesoftware has access to each individual voltage measurement made at eachpatch during each excitation of each pair of electrodes.

The raw patch data is used to determine the “raw” location in threedimensional space (x, y, z) of the electrodes inside the heart, such asthe roving electrode 230. The patch data is also used to create arespiration compensation value used to improve the raw location data forthe electrode locations.

In use, the roving electrode 230 is swept around in the heart chamberwhile the heart is beating collecting a large number of electrodelocations. Electrode 230 may be moved manually by a physician/clinicianor, alternatively, may be manipulated by a robotic system that isdriven, at least in part, by system 30. These data points are taken atall stages of the heart beat and without regard to the cardiac phase.Since the heart changes shape during contraction only a small number ofthe points represent the maximum heart volume. By selecting the mostexterior points, it is possible to create a “shell” representing theshape of the tissue. The location attribute of the electrodes within theheart are measured while the electric field is impressed on the heart bythe surface patch electrodes.

It is possible to also collect electrophysiological (EP) data and ECIdata at the same time that the location data is collected. If the ECIdata, for example, is collected at the same time the location data iscollected, a particular set of ECI data may be associated by the ECU 32with a particular location. This data may later be used in a number offashions. First, the ECI data may be used to determine or assist indetermining which location data points represent the outermost datapoints, or those points that are in actual contact with the tissue 226,and thus, are the most reliable points for generating the shellrepresenting the shape of the tissue 226.

Likewise, the stored ECI data may be used to generate an ECI map, whichcan be used to display tissue characteristics to the operator, e.g.,display tissue types, existing lesions from prior procedures, and thelike. Likewise, it would be advantageous to allow the operator to addmarkers to the map, e.g., to mark manually mark a location he expects alesion to have formed, but which is not reflected in an ECI reading, orto allow for the automatic marking of locations that have certaincharacteristics or that are of interest. While the above discusses thecombination of ECI with location data, it is understood that thelocation data can also be combined with CECI data, or ALI data as well.

The combination of ECI, CECI, or ALI data with a robotic system would beparticularly advantageous, as ECI/CECI/ALI assisted electroanatomicalmaps could be quickly and safely generated by a robotic system. As ECIwould allow the robotic controller to slow the system as it approachedtissue, it would increase safety as well as accuracy. In addition, ECIdata, CECI data, ALI data, or any of the other data described abovewould allow the system to highlight areas of concern for the roboticcontroller to return to for further ablation.

The stored ECI data along with the location data can also be used laterin the procedure to provide a baseline comparison to a current ECIreading, and thus, demonstrate if tissue changes have occurred, e.g.,due to ablation. A map of these tissue changes can be generated, e.g.,displaying a change in ECI (ΔECI) or a rate of change in ECI. Thisinformation can be displayed in a number of fashions, with, for example,different colors on a 3D map of the subject tissue representingparticular ECI values, or representing changes in ECI values (e.g.,ΔECI). This data can be placed onto a geographical map of the locationpoints selected as the shell for display.

Additionally, the system 30 may include the ECU 32 and the display 34among other components. However, in another exemplary embodiment, theECU 32 is a separate and distinct component that is electricallyconnected to the system 30.

In addition to the above, the present invention may also findapplication in systems having multiple electrodes used for mapping theheart or other tissues, obtaining electrophysiological (EP) informationabout the heart or other tissues or ablating tissue. Referring to FIG.29, one example of an EP catheter 244 is shown. The EP catheter 244 maybe a non-contact mapping catheter such as the catheter sold by St. JudeMedical, Atrial Fibrillation Division, Inc. under the registeredtrademark “ENSITE ARRAY.” Alternatively, the catheter 244 may comprise acontact mapping catheter in which measurements are taken through contactof the electrodes with the tissue surface. The catheter 244 includes aplurality of EP mapping electrodes 246. The electrodes 246 are placedwithin electrical fields created in the body 17 (e.g., within theheart). The electrodes 246 experience voltages that are dependent on theposition of the electrodes 246 relative to the tissue 16. Voltagemeasurement comparisons made between the electrodes 246 can be used todetermine the position of the electrodes 246 relative to the tissue 16.The electrodes 246 gather information regarding the geometry of thetissue 16 as well as EP data. For example, voltage levels on the tissuesurface over time may be projected on an image or geometry of the tissueas an activation map. The voltage levels may be represented in variouscolors and the EP data may be animated to show the passage ofelectromagnetic waves over the tissue surface. Information received fromthe electrodes 246 can also be used to display the location andorientation of the electrodes 246 and/or the tip of the EP catheter 244relative to the tissue 16. The electrodes 246 may be formed by removinginsulation from the distal end of a plurality of braided, insulatedwires 248 that are deformed by expansion (e.g., through use of aballoon) into a stable and reproducible geometric shape to fill a space(e.g., a portion of a heart chamber) after introduction into the space.

In the case of contact mapping catheters, the ECI can be used todetermine which the electrodes 246 are in contact with or in closeproximity to the tissue 16 so that only the most relevant information isused in mapping the tissue 16 or in deriving EP measurements or so thatdifferent data sets are more properly weighted in computations. As withthe systems described hereinabove, the signal source 61 of the sensingcircuit 26 may generate excitation signals across source connectorsSOURCE (+) and SOURCE (−) defined between one or more electrodes 246 andthe patch electrode 22. The impedance sensor 58 may then measure theresulting voltages across sense connectors SENSE (+) and SENSE (−))defined between each electrode 246 and the patch electrode 20. The ECU32 may then determine which the electrodes 246 have the highestimpedance and/or ECI to determine the most relevant electrodes 246 forpurposes of mapping or EP measurements. Similarly, in the case of amultiple electrode ablation catheter (not shown), the ECI can be used todetermine which electrodes are in contact with the tissue 16 so thatablation energy is generated through only those electrodes, or can beused to adjust the power delivered to different electrodes to providesufficient power to fully ablate the relevant tissue.

In either contact or non-contact mapping catheters, the multipleelectrodes can provide a stable and highly accurate method of measuringchanges in ECI over time, and thus can be used to determine the efficacyof an ablation. For example, the multiple electrodes 246 can eachprovide data for calculating an ECI value for that electrode. As anablation catheter ablates tissue 16, the ECI values of the nearestelectrodes will change dramatically, allowing the ECU 32 to calculatethe location and efficacy of the lesion formed. The specific methods ofcalculating location will depend on the nature and shape of the mappingcatheter, e.g., spherical, cylindrical, lariat, but may involve usingLaPlace's equation and/or boundary element analysis as disclosed in U.S.Pat. No. 6,978,168 entitled “Software for Mapping Potential Distributionof a Heart Chamber,” the disclosure of which is hereby incorporatedherein by reference in its entirety.

The present invention also permits simultaneous measurements by multipleelectrodes 246 on the catheter 244, or multiple measurements by a singleelectrode using multiple frequencies or duty cycles. Signals havingdistinct frequencies or multiplexed in time can be generated for eachelectrode 246. In one constructed embodiment, for example, signals withfrequencies varying by 500 Hz around a 20 kHz frequency were used toobtain simultaneous distinct measurements from multiple electrodes 246.Because the distinct frequencies permit differentiation of the signalsfrom each electrode 246, measurements can be taken for multipleelectrodes 246 simultaneously thereby significantly reducing the timerequired for mapping and/or EP measurement procedures. Microelectronicspermits precise synthesis of a number of frequencies and at precisequadrature phase offsets necessary for a compact implementation ofcurrent sources and sense signal processors. The extraction ofinformation in this manner from a plurality of transmitted frequenciesis well known in the field of communications as quadrature demodulation.Alternatively, multiple measurements can be accomplished essentiallysimultaneously by multiplexing across a number of electrodes with asingle frequency for intervals of time less than necessary for asignificant change to occur.

In accordance with another aspect of the invention, and as brieflydescribed above, the system 10 may take the form of an automatedcatheter system 250, such as, for example and without limitation, arobotic catheter system or a magnetic-based catheter system. As will bedescribed below, the automated catheter system 250 may be fully orpartially automated, and so may allow for at least a measure of usercontrol through a user input.

In the embodiment wherein the automated catheter system 250 is a roboticcatheter system (i.e., robotic catheter system 250), a robot is used,for example, to control the movement of the catheter 14 and/or to carryout therapeutic, diagnostic, or other activities. In an exemplaryembodiment, the robotic catheter system 250 may be configured such thatinformation relating to contact sensing, proximity sensing, and/orlesion formation determined, for example, using the above-describedcalculated ECI, CECI, ALI, or other index or calculated indicator, maybe communicated from the ECU 32 to a controller or control system 252 ofthe robotic catheter system 250. In an exemplary embodiment, the ECU 32and the controller 252 are one in the same. However, in anotherexemplary embodiment, the two are separate and distinct components. Forease of description purposes only, the following description will bedirected to the latter, separate and distinct arrangement. It should benoted, however, that the embodiment wherein the controller 250 and theECU 32 are the same remains within the spirit and scope of the presentinvention. The information communicated to the controller 252 may be inthe form of the signal(s) described above representative of an indicatorrelating to contact, proximity, and/or lesion formation. As will bedescribed in greater detail below, the controller/control system 252 mayuse this information in the control and operation of the roboticcatheter system 250. With reference to FIGS. 30 and 31, the roboticcatheter system 250 will be briefly described. A full description of therobotic catheter system 250 is set forth in commonly-assigned andco-pending U.S. patent application Ser. No. 12/347,811 entitled “RoboticCatheter System,” the disclosure of which is hereby incorporated byreference herein in its entirety.

Accordingly, FIGS. 30 and 31 illustrate the robotic catheter system 250.The robotic catheter system 250 provides the ability for precise anddynamic automated control in, for example, diagnostic, therapeutic,mapping, and ablative procedures. In an exemplary embodiment, therobotic catheter system 250 includes one or more robotic cathetermanipulator assemblies 254 supported on a manipulator support structure256. The robotic catheter manipulator assembly 254 may include one ormore removably mounted robotic catheter device cartridges 258, forexample, that are generally linearly movable relative to the roboticcatheter manipulator assembly 254 to cause the catheter associatedtherewith (i.e., catheter 14) to be moved (e.g., advanced, retracted,etc.). The catheter manipulator assembly 254 serves as the mechanicalcontrol for the movements or actions of the cartridge 258. The roboticcatheter system 250 may further include a human input device and controlsystem (“input control system”) 260, which may include a joystick andrelated controls with which a physician/clinician may interact tocontrol the manipulation of the cartridge 258, and therefore, thecatheter 14 of the system 250. The robotic catheter system 250 may stillfurther include an electronic control system 262, which, in an exemplaryembodiment, consists of or includes the controller 252, that translatesmotions of the physician/clinician at the input device into a resultingmovement of the catheter. As with the system 10 described above, therobotic catheter system 250 may further include the visualization,mapping and navigation system 30, to provide the clinician/physicianwith real-time or near-real-time positioning information concerning thecatheter and various types of anatomical maps, models, and/or geometriesof the cardiac structure of interest, for example.

In addition to, or instead of, the manual control provided by the inputcontrol system 260, the robotic catheter system 250 may involveautomated catheter movement. For example, in one exemplary embodiment, aphysician/clinician may identify locations (potentially forming a path)on a rendered computer model of the cardiac structure. The system 250can be configured to relate those digitally selected points to positionswithin the patient's actual/physical anatomy, and may command andcontrol the movement of the catheter 14 to defined positions. Once in adefined position, either the physician/clinician or the system 250 couldperform desired treatment or therapy, or perform diagnostic evaluations.The system 250 could enable full robotic control by using optimized pathplanning routines together with the visualization, mapping, andnavigation system 30.

As briefly described above, in an exemplary embodiment, informationrelating to contact sensing, proximity sensing, and/or lesion formationis input into controller 252 and may be used in the control andoperation of the robotic catheter system 250. In an exemplaryembodiment, the information (e.g., ECI, CECI, ALI, etc.) is generatedby, for example, the ECU 32 as described in great detail above. Thisinformation is then communicated by the ECU 32 to the controller 252. Inone exemplary embodiment the information is simply stored within therobotic catheter system 250. Accordingly, no affirmative action is takenby the controller 252, or any other component of the robotic cathetersystem 250, in response to the information. In another exemplaryembodiment, however, the information relating to contact, proximity,and/or lesion formation may be used by the robotic catheter system 250to control one or more aspects of the operation of the system 250.

More particularly, in an exemplary embodiment, when it is determined,based on the calculated or determined index (e.g., ECI, ALI, CECI, etc.)described in great detail above, that the electrode 12 is in contactwith the tissue 16, the controller 252 is configured to stop themovement of the catheter so as to prevent, or at least substantiallyreduce, the risk of the catheter pushing through, puncturing, orotherwise causing damage to the tissue. The controller 252 may also beconfigured to direct diagnostic or therapeutic activities once contactis sensed. For example, the controller 252 may be configured to initiatean ablative action once contact is sensed. In such an instance, thecontroller 252 would be connected to the ablation generate 24 eitherdirectly or indirectly through, for example, the ECU 32 to allowcommunication between the controller 252 and the ablation generate 24 toinitiate ablative action.

Similarly, in another exemplary embodiment, when it is determined, basedon the calculated or determined index (e.g., ECI, ALI, CECI, etc.)described in great detail above, that the electrode 12 is within acertain distance of the tissue 16 such that it is in close proximity tothe tissue 16, the controller 252 may be configured to cause themovement of the catheter to stop, or to cause the speed at which theelectrode 12 approaches the tissue 16 to be reduced. Conversely, thecontroller 252 may be further configured to cause the speed at which thecatheter is travelling to increase if it is determined that theelectrode 12 is a sufficient distance from the tissue 16. The controller252 may be further configured to direct diagnostic or therapeuticactivities depending on the sensed proximity of the electrode 12 to thetissue 16. As described above, in such an instance, the controller 252would be connected to the ablation generate 24 either directly orindirectly through, for example, the ECU 32 to allow communicationbetween the controller 252 and the ablation generate 24 to initiateablative action.

Finally, in yet another exemplary embodiment, information relating tolesion formation may be used by the robotic catheter system 250 in anumber of ways. For example, in one embodiment, the controller 252 maybe configured to direct the catheter 14 to travel to a location wheretissue was to be ablated, and then travel over the expected ablationsite. More particularly, the controller 252 may be configured to controlthe movement of the catheter 14 to revisit an ablation sitepost-ablation and to cause the electrode 12 to travel along an ablationline or about an ablated area. This permits the system 250, as describedin great detail above and using the calculated or determined index(e.g., ECI, ALI, CECI, etc.) also described in great detail above, tosearch for gaps in an ablation line or to determine whether tissue at anablation site that should have been changed (e.g., ablated) was, infact, changed (e.g., ablated). If unchanged/insufficiently changed(e.g., unablated or not fully ablated) tissue is found, the controller252 may cause the catheter 14 to stop and inquire as to whether thetissue should be changed (e.g., ablated). This inquiry may be directedto a physician/clinician, the ECU 32, or another component of the system250. If the answer is “yes,” the controller 252 may be configured todirect the ablation generate 24 to initiate ablative action. In such aninstance, the controller 252 would be connected to the ablation generate24 either directly or indirectly through, for example, the ECU 32 toallow communication between the controller 252 and the ablation generate24 to initiate ablative action. Alternatively, whenunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue is found that the controller 252 knows should be changed (e.g.,ablated), the controller 252 may cause the ablation generate 24 toinitiate ablative action automatically and without inquiry.

In another exemplary embodiment, instead of or in addition to searchingfor unchanged/insufficiently changed (e.g., unablated or not fullyablated) tissue, the robotic control of the catheter movement may permitthe system 250 to, as described in great detail above, assess the extentor quality of lesions formed in the tissue. If it is determined, basedon the calculated or determined index (e.g., ECI, ALI, CECI, etc.)described in great detail above, that a particular area of tissuerequires additional ablation, the controller 252 may cause the catheterto stop and inquire as to whether the tissue should be re-ablated. Thisinquiry may be directed to a physician/clinician the ECU 32, or anothercomponent within the system 250. If the answer is “yes,” the controller252 may be configured to direct the ablation generate 24 to initiateablative action. In such an instance, the controller 252 would beconnected to the ablation generate 24 either directly or indirectlythrough, for example, the ECU 32 to allow communication between thecontroller 252 and the ablation generate 24 to initiate ablative action.Alternatively, when tissue is found that requires additional ablation,the controller 252 may be configured to cause the ablation generate 24to initiate ablative action automatically and without inquiry.

In another exemplary embodiment, rather than controlling the movement ofthe catheter 14 to search for unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue or to determine the quality ofprevious ablation, the controller 252 may be configured to direct thecatheter to travel to a known location requiring ablation/re-ablation,and then directing the ablation generate 24 to initiate an ablativeaction once the desired location is reached. Alternatively, thecontroller 252 may be configured to move the catheter 14 to a desiredlocation and then stop to allow for an inquiry to a physician/clinician,the ECU 32, or another component of system 250 to determine whetherablation should be initiated.

It should be noted that in each of the embodiments described above, thecontroller 252 may be configured to respond to a user input by aphysician/clinician via the input control system 260, or may configuredto carry out the processes described above in a fully or partiallyautomated fashion requiring little or no user involvement.

With reference to FIG. 32, an exemplary embodiment of the automatedcatheter guidance system 250 comprising a magnetic-based catheter system(i.e., magnetic-based catheter system 250′) is illustrated. In oneexemplary embodiment, one or more externally generated magnetic fieldsproduced by one or more electromagnets are used to move, guide, and/orsteer a magnetically-tipped catheter through a patient's body. Theexternally generated magnetic fields exert a desired torque on thecatheter to cause the position of the catheter to be manipulated in adesired way (e.g., advance, retract, bend, rotate, speed up, slow down,etc.). Accordingly, as with the robotic catheter system described above,the magnetic fields may be used to control the movement of the catheter14 and/or to allow the system 10 to carry out therapeutic, diagnostic,or other activities at given locations within the patient's body. A fulldescription of a magnetic-based catheter system is set forth in U.S.Pat. No. 6,507,751 entitled “Method and Apparatus Using Shaped Field ofRepositionable Magnet to Guide Implant,” and U.S. Published PatentApplication No. 2007/0016006 A1 entitled “Apparatus and Method forShaped Magnetic Field Control for Catheter, Guidance, Control, andImaging,” the disclosures of which are hereby incorporated by referenceherein in their entireties.

In an exemplary embodiment, the magnetic-based catheter system 250′ maybe configured such that information relating to contact sensing,proximity sensing, and/or lesion formation determined, for example,using the above-described calculated ECI, CECI, ALI, or other index orcalculated indicator, may be communicated from the ECU 32 to acontroller or control system 252′ of the magnetic-based catheter system250′. In an exemplary embodiment, the ECU 32 and the controller 252′ areone in the same. However, in another exemplary embodiment, the two areseparate and distinct components. For ease of description purposes only,the following description will be directed to the latter, separate anddistinct arrangement. It should be noted, however, that the embodimentwherein the controller 250′ and the ECU 32 are the same remains withinthe spirit and scope of the present invention. The informationcommunicated to the controller 252′ may be in the form of the signal(s)described above representative of an indicator relating to contact,proximity, and/or lesion formation. As will be described in greaterdetail below, the controller/control system 252′ may use thisinformation in the control and operation of the magnetic-based cathetersystem 250′.

As with the robotic catheter system described above, the magnetic-basedcatheter system 250′ provides the ability for precise and dynamicautomated control in, for example, diagnostic, therapeutic, mapping, andablative procedures. In an exemplary embodiment, the magnetic-basedcatheter system 250′ includes somewhat similar structure to that of therobotic catheter system described above to effect the movement of thecatheter 14. For example, system 250′ may comprise a cathetermanipulator assembly 254′ that includes, in part, one or more externalmagnetic field generators configured to create the magnetic field(s)required to induce the movement of the catheter 14, and a magneticelement 255 mounted thereon or therein. The system 250′ may furthercomprise support structures and the like to support catheter 14. As alsowith the robotic catheter system, the magnetic-based catheter system250′ may further include a human input device and control system (“inputcontrol system”), which may include a joystick and related controls withwhich a physician/clinician may interact to control the manipulation thecatheter 14. In one exemplary embodiment, the system 250′ is configuredsuch that the physician or clinician may input a command for thecatheter to move in a particular way. The system 250′ processes thatinput and adjusts the strength and/or orientation of the externalmagnetic fields to cause the catheter 14 to move as commanded. Themagnetic-based catheter system 250′ may also still further include anelectronic control system, which, as with the electronic control systemof the robotic catheter system described above, may consist of orinclude the controller 252′, that translates motions of thephysician/clinician at the input device into a resulting movement of thecatheter. Finally, in an exemplary embodiment, the magnetic-basedcatheter system 250′ may further include the visualization, mapping andnavigation system 30, to provide the clinician/physician with real-timeor near-real-time positioning information concerning the catheter andvarious types of anatomical maps, models, and/or geometries of thecardiac structure of interest, for example.

As briefly described above, in an exemplary embodiment, informationrelating to contact sensing, proximity sensing, and/or lesion formationis input into controller 252′ and may be used in the control andoperation of the magnetic-based catheter system 250′. In an exemplaryembodiment, the information (e.g., ECI, CECI, ALI, etc.) is generatedby, for example, the ECU 32 as described in great detail above. Thisinformation is then communicated by the ECU 32 to the controller 252′.In one exemplary embodiment the information is simply stored within themagnetic-based catheter system 250′. Accordingly, no affirmative actionis taken by the controller 252′, or any other component of themagnetic-based catheter system 250′, in response to the information. Inanother exemplary embodiment, however, the information relating tocontact, proximity, and/or lesion formation may be used by themagnetic-based catheter system 250′ to control one or more aspects ofthe operation of the system 250′.

More particularly, in an exemplary embodiment, when it is determined,based on the calculated or determined index (e.g., ECI, ALI, CECI, etc.)described in great detail above, that the electrode 12 is in contactwith the tissue 16, the controller 252′ is configured to stop themovement of the catheter so as to prevent, or at least substantiallyreduce, the risk of the catheter pushing through, puncturing, orotherwise causing damage to the tissue. Accordingly, the controller 252′is configured to adjust the external magnetic field to cause thecatheter 14 to stop moving. The controller 252′ may also be configuredto direct diagnostic or therapeutic activities once contact is sensed.For example, the controller 252′ may be configured to initiate anablative action once contact is sensed. In such an instance, thecontroller 252′ would be connected to the ablation generate 24 eitherdirectly or indirectly through, for example, the ECU 32 to allowcommunication between the controller 252′ and the ablation generate 24to initiate ablative action.

Similarly, in another exemplary embodiment, when it is determined, basedon the calculated or determined index (e.g., ECI, ALI, CECI, etc.)described in great detail above, that the electrode 12 is within acertain distance of the tissue 16 such that it is in close proximity tothe tissue 16, the controller 252′ may be configured to cause themovement of the catheter to stop, or to cause the speed at which theelectrode 12 approaches the tissue 16 to be reduced, by adjusting thestrength and/or orientation of the external magnetic field. Conversely,the controller 252′ may be further configured to cause the speed atwhich the catheter is travelling to increase if it is determined thatthe electrode 12 is a sufficient distance from the tissue 16. Thecontroller 252′ may be further configured to direct diagnostic ortherapeutic activities depending on the sensed proximity of theelectrode 12 to the tissue 16. As described above, in such an instance,the controller 252′ would be connected to the ablation generate 24either directly or indirectly through, for example, the ECU 32 to allowcommunication between the controller 252′ and the ablation generate 24to initiate ablative action.

Finally, in yet another exemplary embodiment, information relating tolesion formation may be used by the magnetic-based catheter system 250′in a number of ways. For example, in one embodiment, the controller 252′may be configured to direct the catheter 14 to travel to a locationwhere tissue was to be ablated, and then travel over the expectedablation site. More particularly, the controller 252′ may be configuredto control the external magnetic field to cause the catheter 14 torevisit an ablation site post-ablation and to cause the electrode 12 totravel along an ablation line or about an ablated area. This permits thesystem 250′, as described in great detail above and using the calculatedor determined index (e.g., ECI, ALI, CECI, etc.) also described in greatdetail above, to search for gaps in an ablation line or to determinewhether tissue at an ablation site that should have been changed (e.g.,ablated) was, in fact, changed (e.g., ablated). Ifunchanged/insufficiently changed (e.g., unablated or not fully ablated)tissue is found, the controller 252′ may cause the catheter 14 to stopand inquire as to whether the tissue should be changed (e.g., ablated).This inquiry may be directed to a physician/clinician, the ECU 32, oranother component of the system 250′. If the answer is “yes,” thecontroller 252′ may be configured to direct the ablation generate 24 toinitiate ablative action. In such an instance, the controller 252′ wouldbe connected to the ablation generate 24 either directly or indirectlythrough, for example, the ECU 32 to allow communication between thecontroller 252′ and the ablation generate 24 to initiate ablativeaction. Alternatively, when unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue is found that the controller 252′knows should be changed (e.g., ablated), the controller 252′ may causethe ablation generate 24 to initiate ablative action automatically andwithout inquiry.

In another exemplary embodiment, instead of or in addition to searchingfor unchanged/insufficiently changed (e.g., unablated or not fullyablated) tissue, the control of the catheter movement may permit thesystem 250′ to, as described in great detail above, assess the extent orquality of lesions formed in the tissue. If it is determined, based onthe calculated or determined index (e.g., ECI, ALI, CECI, etc.)described in great detail above, that a particular area of tissuerequires additional ablation, the controller 252′ may cause the catheterto stop and inquire as to whether the tissue should be re-ablated. Thisinquiry may be directed to a physician/clinician the ECU 32, or anothercomponent within the system 250′. If the answer is “yes,” the controller252′ may be configured to direct the ablation generate 24 to initiateablative action. In such an instance, the controller 252′ would beconnected to the ablation generate 24 either directly or indirectlythrough, for example, the ECU 32 to allow communication between thecontroller 252′ and the ablation generate 24 to initiate ablativeaction. Alternatively, when tissue is found that requires additionalablation, the controller 252′ may be configured to cause the ablationgenerate 24 to initiate ablative action automatically and withoutinquiry.

In another exemplary embodiment, rather than controlling the movement ofthe catheter 14 to search for unchanged/insufficiently changed (e.g.,unablated or not fully ablated) tissue or to determine the quality orextent of a previous ablation, the controller 252′ may be configured todirect the catheter to travel to a known location requiringablation/re-ablation, and then directing the ablation generate 24 toinitiate an ablative action once the desired location is reached.Alternatively, the controller 252′ may be configured to move thecatheter 14 to a desired location and then stop to allow for an inquiryto a physician/clinician, the ECU 32, or another component of system250′ to determine whether ablation should be initiated.

It should be noted that in each of the embodiments described above, thecontroller 252′ may be configured to respond to a user input by aphysician/clinician via the input control system, or may configured tocarry out the processes described above in a fully or partiallyautomated fashion requiring little or no user involvement.

Although several embodiments of this invention have been described abovewith a certain degree of particularity, those skilled in the art couldmake numerous alterations to the disclosed embodiments without departingfrom the scope of this invention. All directional references (e.g.,upper, lower, upward, downward, left, right, leftward, rightward, top,bottom, above, below, vertical, horizontal, clockwise andcounterclockwise) are only used for identification purposes to aid thereader's understanding of the present invention, and do not createlimitations, particularly as to the position, orientation, or use of theinvention. Joinder references (e.g., attached, coupled, connected, andthe like) are to be construed broadly and may include intermediatemembers between a connection of elements and relative movement betweenelements. As such, joinder references do not necessarily infer that twoelements are directly connected and in fixed relation to each other. Itis intended that all matter contained in the above description or shownin the accompanying drawings shall be interpreted as illustrative onlyand not as limiting. Changes in detail or structure may be made withoutdeparting from the invention as defined in the appended claims.

What is claimed is:
 1. A guidance system for a catheter, comprising: anelectronic control unit (ECU) configured to: analyze first and secondcomponents of a complex impedance between an electrode and tissue;analyze a state of contact between the electrode and the tissue; andassess at least one lesion site on the tissue according to the first andsecond complex impedance components and according to the state ofcontact; and a display device, electrically coupled with said ECU,configured to provide feedback to a user for manipulating the catheteraccording to said lesion site assessment.
 2. The guidance system ofclaim 1, wherein the state of contact comprises one or more of a contactpressure, a contact force, a temperature, a change in temperature, and afluid flow rate.
 3. The guidance system of claim 1, wherein said ECU isconfigured to assess the at least one lesion site by calculating anindex responsive to at least the first and second complex impedancecomponents and to the state of contact.
 4. The guidance system of claim3, wherein said ECU is configured to assess the at least one lesion siteby calculating an index rate by: receiving first location coordinatescorresponding to a first location of the electrode and second locationcoordinates corresponding to a second location of the electrode;calculating an index change between a first index calculated responsiveto first and second components of a first complex impedance acquiredwhile said electrode is located at said first location and a secondindex calculated responsive to first and second components of a secondcomplex impedance acquired while said electrode is located at saidsecond location over a predetermined time interval; calculating a changein said location coordinates; and calculating an index rate by dividingsaid index change by said change in said location coordinates of saidelectrode.